WO2011140249A2 - Antibodies that bind csf1r - Google Patents
Antibodies that bind csf1r Download PDFInfo
- Publication number
- WO2011140249A2 WO2011140249A2 PCT/US2011/035231 US2011035231W WO2011140249A2 WO 2011140249 A2 WO2011140249 A2 WO 2011140249A2 US 2011035231 W US2011035231 W US 2011035231W WO 2011140249 A2 WO2011140249 A2 WO 2011140249A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- seq
- light chain
- heavy chain
- antibody
- Prior art date
Links
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 65
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims abstract description 64
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 44
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 44
- 239000002157 polynucleotide Substances 0.000 claims abstract description 44
- 108091011896 CSF1 Proteins 0.000 claims abstract description 38
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims abstract description 38
- 206010065687 Bone loss Diseases 0.000 claims abstract description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 112
- 230000027455 binding Effects 0.000 claims description 110
- 102000039446 nucleic acids Human genes 0.000 claims description 64
- 108020004707 nucleic acids Proteins 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 239000003446 ligand Substances 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 210000001616 monocyte Anatomy 0.000 claims description 34
- 102100033499 Interleukin-34 Human genes 0.000 claims description 31
- 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 26
- 230000035755 proliferation Effects 0.000 claims description 26
- 230000026731 phosphorylation Effects 0.000 claims description 25
- 238000006366 phosphorylation reaction Methods 0.000 claims description 25
- 230000000010 osteolytic effect Effects 0.000 claims description 22
- 230000004083 survival effect Effects 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010027476 Metastases Diseases 0.000 claims description 13
- 230000009401 metastasis Effects 0.000 claims description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 11
- 102000052833 human CSF1R Human genes 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 21
- 241000282414 Homo sapiens Species 0.000 description 223
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 57
- 102000004196 processed proteins & peptides Human genes 0.000 description 38
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 229920001184 polypeptide Polymers 0.000 description 37
- 230000000903 blocking effect Effects 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 238000006467 substitution reaction Methods 0.000 description 30
- 239000013598 vector Substances 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 201000010099 disease Diseases 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 230000006870 function Effects 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000012636 effector Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 12
- 101100396731 Homo sapiens IL34 gene Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 102000053925 human CSF1 Human genes 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 9
- 241000282567 Macaca fascicularis Species 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000002254 cytotoxic agent Substances 0.000 description 8
- 231100000599 cytotoxic agent Toxicity 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000004968 inflammatory condition Effects 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 208000003076 Osteolysis Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 6
- -1 semisolid Substances 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101100168715 Mus musculus Csf1r gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001211 electron capture detection Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- 206010000228 Abortion infected Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 101100446590 Arabidopsis thaliana FIM5 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101150106011 FIM2 gene Proteins 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 101710181549 Interleukin-34 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000002359 Septic Abortion Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000031752 chronic bilirubin encephalopathy Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- Antibodies that bind CSF IR are provided.
- Antibody heavy chains and light chains that are capable of forming antibodies that bind CSFI R are also provided.
- antibodies, heavy chains, and light chains comprising one or more particular complementarity determining regions (CDRs) are provided.
- Polynucleotides encoding antibodies to CSFIR are provided. Polynucleotides encoding antibody heavy chains or lights chains are also provided. Methods of treatment using antibodies to CSF IR are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
- Colony stimulating factor 1 receptor (referred to herein as CSFIR; also referred to in the art as FMS, FIM2, C-FMS, and CD115) is a single-pass
- transmembrane receptor with an N-terminal extracellular domain (ECD) and a C- terminal intracellular domain with tyrosine kinase activity.
- ECD extracellular domain
- CSF1 or the interleukin 34 ligand referred to herein as IL34; Lin et al, Science 320: 807-11 (2008)
- IL34 interleukin 34 ligand
- CSF1 and IL34 stimulate monocyte survival, proliferation, and differentiation into macrophages.
- CSF1 tumor-associated macrophages
- TAMs tumor-associated macrophages
- CSF1 has been found to promote tumor growth and progression to metastasis in, for example, human breast cancer xenografts in mice. See, e.g., Paulus et al., Cancer Res. 66: 4349-56 (2006).
- CSFIR appears to play a role in osteolytic bone destruction in bone metastasis, as a small molecule inhibitor of receptor tyrosine kinase activity suppresses that destruction. See, e.g., Ohno et al., Mol. Cancer Ther. 5: 2634-43 (2006).
- CSF1 and its receptor have also been found to be involved in various inflammatory and autoimmune diseases. See, e.g., Hamilton, Nat. Rev. 8: 533-44 (2008). For example, synovial endothelial cells from joints afflicted with rheumatoid arthritis have been found to produce CSF1 , suggesting a role for CSF1 and its receptor in the disease.
- Blocking CSFIR activity with an antibody results in positive clinical effects in mouse models of arthritis, including a reduction in the destmction of bone and cartilage and a reduction in macrophage numbers. See, e.g., Kitaura et al., J. Clin. Invest. 1 15: 3418-3427 (2005).
- Mature differentiated myeloid lineage cells such as macrophages, microglial cells, and osteoclasts contribute to pathology of various diseases such as rheumatoid arthritis, multiple sclerosis and diseases of bone loss.
- Differentiated myeloid lineage cells are derived from peripheral blood monocyte intermediates.
- CSFI R stimulation contributes to development of monocytes from bone marrow precursors, to monocyte proliferation and sui'vival, and to differentiation of peripheral blood monocytes into differentiated myeloid lineage cells such as macrophages, microglial cells, and osteoclasts.
- CSFIR stimulation thus contributes to proliferation, sui'vival, activation, and maturation of differentiated myeloid lineage cells, and in the pathologic setting, CSFI R stimulation contributes to the ability of differentiated myeloid lineage cells to mediate disease pathology.
- the present inventors have invented a new set of antibodies, including humanized antibodies, directed against human CSFI R extracellular domain (CSFIR ECD).
- CSFIR ECD humanized antibodies
- a Fab phage display library was made from spleens of mice that were immunized with a human CSFIR ECD-Fc fusion protein. 1056 phage clones expressing Fabs that bind to CSF-1R ECD-Fc were isolated through panning of this library. When the 1056 Fabs were expressed as purified protein, 668 were found to bind to CSFIR ECD. Of those 668 binding Fabs, only 121 Fabs blocked binding of CSF1 and/or IL34 to CSFI R.
- humanized antibodies retained subnanomolar binding affinities for human CSFIR ECD. See, e.g., Table 5. These humanized antibodies block binding of both ligands CSFl and IL34 to human CSFIR, and many also block binding of both CSFl and IL34 to cynomolgus monkey CSFIR. See, e.g., Table 4.
- Humanized versions of 0301 and 031 1 retained similarly strong binding to both human and cynomolgus monkey CSFIR ECD, with binding affinity differences for the two species of less than about 2-fold.
- phosphorylation of human CSFIR and also block ligand-induced proliferation and survival responses in primary human monocytes. See, e.g., Tables 6 and 7, and Figures 10 and 1 1.
- these antibodies are useful for treating diseases involving, for example, ligand-induced proliferation and survival responses in primary human monocytes.
- Blocking CSFlR-induced responses with an anti-CSFIR antibody should inhibit proliferation, survival, activation, maturation of differentiated myeloid lineage cells and attenuate their ability to mediate disease pathology.
- blocking CSFlR-induced responses with an anti-CSFI R antibody should inhibit differentiation of peripheral blood monocyte intermediates into differentiated myeloid lineage cells, decreasing the number of pathology-mediating differentiated myeloid lineage cells.
- the humanized anti-CSFIR antibodies described herein can be used to treat chronic diseases with extant symptoms by inhibiting the ability of differentiated myeloid lineage cells to mediate disease pathology.
- the humanized antibodies can also be used to treat chronic diseases that are relapsing and remitting in nature by inhibiting the development of new pathology-mediating myeloid lineage cells differentiated from peripheral blood monocytes during the remitting phase of the disease, thus attenuating the number of and new formation of the pathology-mediating cells.
- an isolated antibody comprising a heavy chain and a light chain is provided, wherein the antibody binds to CSF1R.
- the heavy chain and/or light chain have the following structure.
- the heavy chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
- the light chain comprises a sequence that is at least 90%o, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
- the heavy chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45
- the light chain comprises a sequence that is at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
- the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (e) SEQ ID NOs: 27, 28, and 29.
- the LC CDR1, LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
- the heavy chain comprises an HC CDR1 , HC CDR2, and HC CDR3, wherein the HC CDR1 , HC CDR2, and HC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 15, 16, and 17; (b) SEQ ID NOs: 21 , 22, and 23; and (c) SEQ ID NOs: 27, 28, and 29; and the light chain comprises an LC CDR1 , LC CDR2, and LC CDR3, wherein the LC CDR1 , LC CDR2, and LC CDR3 comprise a set of sequences selected from: (a) SEQ ID NOs: 18, 19, and 20; (b) SEQ ID NOs: 24, 25, and 26; and (c) SEQ ID NOs: 30, 31 , and 32.
- an isolated antibody comprising a heavy chain and a light chain, wherein the antibody comprises:
- a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 41 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 47; and (j) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 48; (k) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 42 and a light chain comprising a sequence that is at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO: 49; (1) a heavy chain comprising a sequence that is at least 95%, at least 97%, at least
- an antibody comprising a heavy chain and a light chain
- the antibody comprises: (a) a heavy chain comprising a heavy chain (HC) CDR1 having the sequence of SEQ ID NO: 15, an HC CDR2 having the sequence of SEQ ID NO: 16, and an HC CDR3 having the sequence of SEQ ID NO: 17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO: 18, a LC CDR2 having the sequence of SEQ ID NO: 19, and a LC CDR3 having the sequence of SEQ ID NO: 20; (b) a heavy chain comprising a heavy chain (HC) CDRl having the sequence of SEQ ID NO: 21 , an HC CDR2 having the sequence of SEQ ID NO: 22, and an HC CDR3 having the sequence of SEQ ID NO: 23, and a light chain comprising a light chain (LC) CDRl having the sequence of SEQ ID NO: 24, a LC
- an antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 60; (b) a heavy chain comprising a sequence of SEQ ID NO: 53 and a light chain comprising a sequence of SEQ ID NO: 61 ; or (c) a heavy chain comprising a sequence of SEQ ID NO: 58 and a light chain comprising a sequence of SEQ ID NO: 65.
- an antibody comprises a heavy chain and a light chain, wherein the antibody comprises: (a) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 60; (b) a heavy chain consisting of the sequence of SEQ ID NO: 53 and a light chain consisting of the sequence of SEQ ID NO: 61 ; or (c) a heavy chain consisting of the sequence of SEQ ID NO: 58 and a light chain consisting of the sequence of SEQ ID NO: 65.
- an antibody is a humanized antibody.
- an antibody is selected from a Fab, an Fv, an scFv, a Fab ⁇ and a (Fab') 2 .
- an antibody is a chimeric antibody.
- an antibody is selected from an IgA, an IgG, and an IgD.
- an antibody is an IgG.
- an antibody is an IgG4.
- an antibody is an IgG4 comprising an S241P mutation in at least one IgG4 heavy chain constant region.
- an antibody binds to human CSF1R and/or binds to cynomolgus CSF1R. In some embodiments, an antibody blocks ligand binding to CSF1 R. In some embodiments, an antibody blocks binding of CSF1 and/or IL34 to CSF1 R. In some embodiments, an antibody inhibits ligand-induced CSF1R phosphorylation. In some embodiments, an antibody inhibits CSF1- and/or IL34-induced CSF1R phosphoiylation. In some embodiments, an antibody binds to human CSF1R with an affinity (K D ) of less than 1 nM. In some embodiments, antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 01- IL34.
- a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
- an isolated nucleic acid comprising a polynucleotide sequence that encodes a heavy chain described above. In some embodiments, an isolated nucleic acid encodes a light chain described above. In some embodiments, an isolated nucleic acid encodes a heavy chain described above and a light chain described above. In some embodiments, a composition is provided, wherein the composition comprises a first nucleic acid that comprises a polynucleotide sequence that encodes a heavy chain described above, and a second nucleic acid that comprises a polynucleotide sequence that encodes a light chain described above.
- a host cell comprising a nucleic acid or a composition described above is provided.
- a host cell is a eukaryotic host cell.
- a host cell is a mammalian host cell.
- a host cell is selected from a CHO cell, a 293 cell, an NSO cell, and a PER.C6 cell.
- a host cell is a 293-6E cell or a DG44 cell.
- methods of treating disease comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R.
- a method of treating multiple sclerosis comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
- a method of treating rheumatoid arthritis comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
- a method of treating osteolytic bone loss comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
- the osteolytic bone loss is selected from osteoporosis, metastasis-induced osteolytic bone loss, and rheumatoid arthritis- induced bone loss.
- a method of treating cancer comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSF1R is provided.
- the cancer is selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cervical cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
- a method of treating an inflammatory condition comprising administering to a patient a pharmaceutical composition comprising an antibody that binds CSFIR is provided.
- antibodies that bind CSF IR and compositions comprising antibodies that bind CSFIR are provided for use in methods of treatment of human or animals. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFIR are provided for use in a method of treating rheumatoid arthritis in a human or animal. In some embodiments, antibodies that bind CSFI R and compositions comprising antibodies that bind CSFI R are provided for use in a method of treating multiple sclerosis in a human or animal. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFI R are provided for use in a method of treating cancer in a human or animal. In some embodiments, antibodies that bind CSFIR and compositions comprising antibodies that bind CSFIR are provided for use in a method of treating an inflammatory condition in a human or animal.
- FIG. 1 shows an alignment of the humanized heavy chain variable regions for each of humanized antibodies Abl to Abl 6, as discussed in Example 4. Boxed residues are amino acids in the human acceptor sequence that were changed back to the corresponding mouse residue.
- FIG. 2 shows an alignment of the humanized light chain variable regions for each of humanized antibodies Abl to Ab 16, as discussed in Example 4 Boxed amino acids are residues in the human acceptor sequence that were changed back to the corresponding mouse residue.
- FIG. 3 shows binding curves for certain humanized antibodies binding to human CSFIR ECD, as described in Example 5.
- Figure 3 A shows binding curves for parental chimeric antibodies (cAb) 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (hO3Ol-LOH0, h0301-L0Hl, h0301-L0H2, h0301-LlH0, h0301 -LlHl , and Ii0301-L1H2, respectively).
- Figure 3B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0H l , Ii0302-L1 H1 , h0302-L2Hl , h0302-L0H2, h0302-LlH2, and h0302-L2H2, respectively).
- Figure 3C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1 , 031 1 .2, 031 1.3 , and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI H 1 , h031 1 -L0H2, and h031 1-L1 H2, respectively).
- FIG. 4 shows binding curves for certain humanized antibodies binding to cynomolgus CSF1 R ECD, as described in Example 5.
- Figure 4A shows binding curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301 -L0Hl , h0301-L0H2, h0301 - L1H0, h0301 -LlH l , and h0301 -Ll H2, respectively).
- Figure 4B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively).
- Figure 4C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1, 031 1.2,
- 031 1.3, and 031 1.4 (h031 1 -LOHl , h0311-LlHl , h031 1 -L0H2, and h031 1 -L1H2, respectively).
- FIG. 5 shows binding curves for certain humanized antibodies binding to mouse CSF1R ECD, as described in Example 5.
- Figure 5 A shows binding curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1, 0301.2, 0302.3,
- FIG. 5B shows binding curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4,
- FIG. 5C shows binding curves for parental cAb 031 1 and humanized antibodies (huAb) 0311.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI H 1 , h031 1 -L0H2, and h031 1 -LI H2, respectively).
- FIG. 6 shows inhibition of CSF1 induced CSF1R phosphorylation by certain humanized antibodies, as described in Example 6.
- Figure 6 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1, 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301 -L0Hl , h0301 -L0H2, h0301- L1H0, h0301 -LlHl , and Ii0301 -L1 H2, respectively).
- Figure 6B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0H l , h0302-L! Hl , h0302-L2H l , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively).
- Figure 6C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1 .1 , 031 1.2, 031 1.3, and 031 1 .4 (h031 1 -L0H1 , h031 1 -L1H1 , h0311 -L0H2, and h0311 -L1H2, respectively).
- FIG. 7 shows inhibition of IL34 induced CSF1R phosphorylation by certain humanized antibodies, as described in Example 6.
- Figure 7 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301 -L0H0, h0301 -L0Hl , h0301 -L0H2, h0301- L1H0, h0301 -LlHl , and h0301-Ll H2, respectively).
- Figure 7B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302-L2Hl , h0302- L0H2, h0302-LlH2, and h0302-L2H2, respectively).
- Figure 7C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -LI HI , h031 1 -L0H2, and h031 1 -LI H2, respectively).
- FIG. 8 shows blocking of human CSF1 binding to cynomolgus CSF1R ECD by certain humanized antibodies, as described in Example 7.
- Figure 8A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301-L0H0, h0301-L0Hl , h0301- L0H2, h0301-LlH0, Ii0301 -L1H1 , and h0301 -LlH2, respectively).
- Figure 8B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , Ii0302-L1H1 , h0302- L2H1 , h0302-L0H2, h0302-LlH2, and h0302-L2H2, respectively).
- Figure 8C shows blocking curves for parental cAb 031 1 and humanized antibodies (huAb) 031 1.1, 031 1.2, 031 1 .3, and 031 1.4 (h031 1 -L0H 1 , h031 1 -L1H1 , h031 1 -L0H2, and h031 1 - L1H2, respectively).
- FIG. 9 shows blocking of human IL34 binding to cynomolgus CSF1R ECD by certain humanized antibodies, as described in Example 7.
- Figure 9 A shows blocking curves for parental cAb 0301 and humanized antibodies (huAb) 0301.1 , 0301.2, 0302.3, 0301.4, 0301.5, and 0301.6 (h0301 -LOH0, h0301 -L0Hl , h0301 - L0H2, h0301 -LlH0, h0301 -LI Hl , and h0301-Ll H2, respectively).
- Figure 9B shows blocking curves for parental cAb 0302 and humanized antibodies (huAb) 0302.1 , 0302.2, 0302.3, 0302.4, 0302.5, and 0302.6 (h0302-L0Hl , h0302-LlHl , h0302- L2H1 , h0302-L0H2, Ii0302-L1H2, and h0302-L2H2, respectively).
- Figure 9C shows blocking curves for parental cAb 0311 and humanized antibodies (huAb) 031 1.1 , 031 1.2, 031 1.3, and 031 1.4 (h031 1 -L0H 1 , h0311 -LI H 1 , h031 1 -L0H2, and h031 1 - L1H2, respectively).
- FIG. 10 shows blocking of CSFl - (A) and IL34- (B) induced CSFIR phosphorylation in CHO cells expressing human CSFIR by humanized antibodies 0301 -L0H0, 0301 -L1 H0, and 031 1 -LOHl , as described in Example 9.
- FIG. 11 shows blocking of CSFl- (A) and IL34- (B) induced monoclyte proliferation/survival responses by humanized antibodies 0301-L0H0, 0301 -LI HO, and 031 1 -LOHl , as described in Example 10.
- FIG. 12A-C shows that humanized antibodies 0301-L0H0, 0301- LIHO, and 031 1-LOHl do not stimulate primary monocyte proliferation or survival, using monocytes from three different donors, as described in Example 11.
- Methods of treating diseases comprising administering novel antibodies to CSF I R are provided. All of the antibodies have binding affinities for human CSFIR ECD of less than 2 nM, and all but two of the humanized antibodies have sub-nanomolar binding affinities for human CSFIR ECD. Further, the new antibodies block binding of both CSFl and IL34 to human CSFIR, and inhibit ligand- induced phosphorylation of human CSFIR. Many of the new antibodies also block binding of CSFl and 1L34 to cynomolgus CSFI R, which facilitates in vivo experiments to support the development of anti-CSFIR antibody therapeutics. The new antibodies are therefore well suited for therapeutic use in human diseases, including, but not limited to, cancer, autoimmune diseases, and inflammatory conditions.
- nucleic acid molecule and “polynucleotide” may be used interchangeably, and refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and/or non-natural nucleotides, and include, but are not limited to, DNA, NA, and PNA.
- Nucleic acid sequence refers to the linear sequence of nucleotides that comprise the nucleic acid molecule or polynucleotide.
- polypeptide and protein are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition.
- the terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like.
- a "polypeptide” refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
- the term “CSFIR” refers herein to the full-length CSFIR, which includes the N-terminal ECD, the transmembrane domain, and the intracellular tyrosine kinase domain, with or without an N-terminal leader sequence.
- the CSFIR is a human CSFIR having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
- CSFIR extracellular domain refers to a CSFIR polypeptide that lacks the intracellular and transmembrane domains.
- CSFIR ECDs include the full-length CSFIR ECD and CSFIR ECD fragments that are capable of binding CSFIR and/or IL34.
- the human full-length CSFIR ECD is defined herein as comprising either amino acids 1 to 512 (i.e., including the leader sequence) or amino acids 20 to 512 (i.e., lacking the leader sequence) of SEQ ID NO: 2.
- a human CSFIR ECD fragment comprises amino acids 20 to 506 of SEQ ID NO: 2 (see SEQ ID NO:5).
- a human CSFIR fragment ends at amino acid 507, 508, 509, 510, or 51 1.
- a cynoCSF 1 R ECD comprises the sequence of SEQ ID NO: 7 (with leader sequence) or amino acids 20 to 506 of SEQ ID NO: 7 (without leader sequence).
- antibody refers to a molecule comprising at least complementarity-determining region (CDR) 1 , CDR2, and CDR3 of a heavy chain and at least CDR1 , CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to antigen.
- the term antibody includes, but is not limited to, fragments that are capable of binding antigen, such as Fv, single-chain Fv (scFv), Fab, Fab', and (Fab') 2 .
- the term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as mouse, human, cynomolgus monkey, etc.
- an antibody comprises a heavy chain variable region and a light chain variable region.
- an antibody comprises at least one heavy chain comprising a heavy chain variable region and at least a portion of a heavy chain constant region, and at least one light chain comprising a light chain variable region and at least a portion of a light chain constant region.
- an antibody comprises two heavy chains, wherein each heavy chain comprises a heavy chain variable region and at least a portion of a heavy chain constant region, and two light chains, wherein each light chain comprises a light chain variable region and at least a portion of a light chain constant region.
- a single-chain Fv or any other antibody that comprises, for example, a single polypeptide chain comprising all six CDRs (three heavy chain CDRs and three light chain CDRs) is considered to have a heavy chain and a light chain.
- the heavy chain is the region of the antibody that comprises the three heavy chain CDRs and the light chain in the region of the antibody that comprises the three light chain CDRs.
- heavy chain variable region refers to a region comprising heavy chain CDRl , framework (FR) 2, CDR2, FR3, and CDR3.
- a heavy chain variable region also comprises at least a portion of an FR1 and/or at least a portion of an FR4.
- a heavy chain CDRl corresponds to Kabat residues 26 to 35;
- a heavy chain CDR2 corresponds to Kabat residues 50 to 65;
- a heavy chain CDR3 corresponds to Kabat residues 95 to 102. See, e.g., Kabat Sequences of Proteins of Immunological Interest (1987 and 1991 , NIH, Bethesda, Md.); and Figure 1.
- a heavy chain CDRl corresponds to Kabat residues 31 to 35; a heavy chain CDR2 corresponds to Kabat residues 50 to 65; and a heavy chain CDR3 corresponds to Kabat residues 95 to 102. See id.
- heavy chain constant region refers to a region comprising at least three heavy chain constant domains, C H 1 , CH2, and CH3.
- Nonlimiting exemplary heavy chain constant regions include ⁇ , ⁇ , and a.
- Nonlimiting exemplary heavy chain constant regions also include ⁇ and ⁇ .
- Each heavy constant region corresponds to an antibody isotype.
- an antibody comprising a ⁇ constant region is an IgG antibody
- an antibody comprising a ⁇ constant region is an IgD antibody
- an antibody comprising an a constant region is an IgA antibody.
- an antibody comprising a ⁇ constant region is an IgM antibody
- an antibody comprising an ⁇ constant region is an IgE antibody.
- IgG antibodies include, but are not limited to, IgG l (comprising a ⁇ constant region), IgG2 (comprising a ⁇ 2 constant region), IgG3 (comprising a 73 constant region), and IgG4 (comprising a ⁇ 4 constant region) antibodies;
- IgA antibodies include, but are not limited to, IgAl (comprising an a] constant region) and lgA2 (comprising an ao constant region) antibodies; and IgM antibodies include, but are not limited to, IgMl and IgM2.
- a heavy chain constant region comprises one or more mutations (or substitutions), additions, or deletions that confer a desired characteristic on the antibody.
- a nonlimiting exemplary mutation is the S241P mutation in the IgG4 hinge region (between constant domains C H 1 and CH2), which alters the lgG4 motif CPSCP to CPPCP, which is similar to the corresponding motif in IgG 1. That mutation, in some embodiments, results in a more stable IgG4 antibody. See, e.g., Angal et al., Mol. Immunol. 30: 105-108 (1993); Bloom et al., Prot. Sci. 6: 407-415 (1997); Schuurman et al., Mol. Immunol. 38: 1-8 (2001 ).
- heavy chain refers to a polypeptide comprising at least a heavy chain variable region, with or without a leader sequence.
- a heavy chain comprises at least a portion of a heavy chain constant region.
- full-length heavy chain refers to a polypeptide comprising a heavy chain variable region and a heavy chain constant region, with or without a leader sequence.
- light chain variable region refers to a region comprising light chain CDRl , framework (FR) 2, CDR2, FR3, and CDR3.
- a light chain variable region also comprises an FR1 and/or an FR4.
- a light chain CDRl coiTesponds to Kabat residues 24 to 34;
- a light chain CDR2 corresponds to Kabat residues 50 to 56;
- light chain constant region refers to a region comprising a light chain constant domain
- CL- Nonlimiting exemplary light chain constant regions include ⁇ and .
- light chain refers to a polypeptide comprising at least a light chain variable region, with or without a leader sequence.
- a light chain comprises at least a portion of a light chain constant region.
- full-length light chain refers to a polypeptide comprising a light chain variable region and a light chain constant region, with or without a leader sequence.
- a "chimeric antibody” as used herein refers to an antibody comprising at least one variable region from a first species (such as mouse, rat, cynomolgus monkey, etc.) and at least one constant region from a second species (such as human, cynomolgus monkey, etc.).
- a chimeric antibody comprises at least one mouse variable region and at least one human constant region.
- a chimeric antibody comprises at least one cynomolgus variable region and at least one human constant region.
- all of the variable regions of a chimeric antibody are from a first species and all of the constant regions of the chimeric antibody are from a second species.
- a “humanized antibody” as used herein refers to an antibody in which at least one amino acid in a framework region of a non-human variable region has been replaced with the corresponding amino acid from a human variable region.
- a humanized antibody comprises at least one human constant region or fragment thereof.
- a humanized antibody is an Fab, an scFv, a (Fab') 2 , etc.
- CDR-grafted antibody refers to a humanized antibody in which the complementarity detemiining regions (CDRs) of a first (non- human) species have been grafted onto the framework regions (FRs) of a second (human) species.
- a "human antibody '' as used herein refers to antibodies produced in humans, antibodies produced in non-human animals that comprise human immunoglobulin genes, such as XenoMouse®, and antibodies selected using in vitro methods, such as phage display, wherein the antibody repertoire is based on a human immunoglobulin sequences.
- leader sequence refers to a sequence of amino acid residues located at the N terminus of a polypeptide that facilitates secretion of a polypeptide from a mammalian cell.
- a leader sequence may be cleaved upon export of the polypeptide from the mammalian cell, forming a mature protein.
- Leader sequences may be natural or synthetic, and they may be heterologous or homologous to the protein to which they are attached.
- Exemplary leader sequences include, but are not limited to, antibody leader sequences, such as, for example, the amino acid sequences of SEQ ID NOs.: 3 and 4, which correspond to human light and heavy chain leader sequences, respectively.
- Nonlimiting exemplary leader sequences also include leader sequences from heterologous proteins.
- an antibody lacks a leader sequence.
- an antibody comprises at least one leader sequence, which may be selected from native antibody leader sequences and heterologous leader sequences.
- vector is used to describe a polynucleotide that may be engineered to contain a cloned polynucleotide or polynucleotides that may be propagated in a host cell.
- a vector may include one or more of the following elements: an origin of replication, one or more regulatory sequences (such as, for example, promoters and/or enhancers) that regulate the expression of the polypeptide of interest, and/or one or more selectable marker genes (such as, for example, antibiotic resistance genes and genes that may be used in coloriinetric assays, e.g., ⁇ - galactosidase).
- expression vector refers to a vector that is used to express a polypeptide of interest in a host cell.
- a "host cell” refers to a cell that may be or has been a recipient of a vector or isolated polynucleotide.
- Host cells may be prokaryotic cells or eukaryotic cells.
- Exemplary eukaiyotic cells include mammalian cells, such as primate or non- primate animal cells; fungal cells, such as yeast; plant cells; and insect cells.
- Nonlimiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6® cells (Cracell), and 293 and CHO cells, and their derivatives, such as 293- 6E and DG44 cells, respectively.
- isolated refers to a molecule that has been separated from at least some of the components with which it is typically found in nature.
- a polypeptide is referred to as “isolated” when it is separated from at least some of the components of the cell in which it was produced.
- a polypeptide is secreted by a cell after expression, physically separating the supernatant containing the polypeptide from the cell that produced it is considered to be “isolating" the polypeptide.
- a polynucleotide is referred to as "isolated" when it is not part of the larger polynucleotide (such as, for example, genomic DNA or mitochondrial DNA, in the case of a DNA polynucleotide) in which it is typically found in nature, or is separated from at least some of the components of the cell in which it was produced, e.g., in the case of an RNA polynucleotide.
- a DNA polynucleotide that is contained in a vector inside a host cell may be referred to as “isolated” so long as that polynucleotide is not found in that vector in nature.
- subject and “patient” are used interchangeably herein to refer to a human.
- methods of treating other mammals including, but not limited to, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, manmialian laboratoiy animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are also provided.
- RA rheumatoid arthritis
- MS multiple sclerosis
- MS multiple sclerosis
- Demyelination occurs when the myelin sheath becomes inflamed, injured, and detaches from the nerve fiber.
- cancer refers to a proliferative disorder associated with uncontrolled cell proliferation, unrestrained cell growth, and decreased cell deathiapoptosis.
- Cancer includes, but is not limited to, breast cancer, prostate cancer, lung cancer, kidney cancer, thyroid cancer, esophageal cancer, melanoma, follicular lymphomas, uveal melanoma, brain cancer, head and neck cancer, pulmonary adenocarcinoma, including, but not limited to, colon cancer, cardiac tumors, pancreatic cancer, retinoblastoma, glioblastoma, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, Kaposi's sarcoma, ovarian cancer, leukemia (including acute leukemias (
- metalastasis and “cancer metastasis” are used interchangeably herein to refer to the ability of a cancer cell to spread to other tissues.
- metalastasis to bone ' ' refers to the ability of certain types of cancer including, but not limited to, breast, prostate, lung, kidney, thyroid, and melanoma, to metastasize to bone.
- osteolytic disorders is used herein to refer to any condition that is caused by an increase in the activity of osteoclasts, which are cells responsible for bone resorption.
- the terms “osteolysis” and “osteolytic bone loss” may be used interchangeably to refer to osteoclast-mediated bone resorption or bone loss associated with an osteolytic disorder.
- Osteolytic disorders may occur in subjects with a predisposition to develop an osteolytic disorder, or they may occur in subjects with a disease that leads to or contributes to an osteolytic disorder by stimulating osteoclast activity.
- the osteolytic disorder may include osteolytic bone loss and cancer metastasis-induced osteolytic bone loss.
- the osteolytic bone disorder includes metabolic bone disease, including endocrinopathies, such as hypercortisolism, hypogonadism, primary or secondaiy hyperparathyroidism, and hyperthyroidism; dietaiy deficiency, including rickets, osteomalacia, scurvy, and malnutrition; osteoporosis; drug use, including glucocorticoids (glucocorticoid- induced osteoporosis), heparin, and alcohol; chronic disease, including malabsorption syndromes; chronic renal failure, including renal osteodystrophy; chronic liver disease, including hepatic osteodystrophy; inherited disease, including osteogenesis imperfecta and homocystinuria; and bone inflammation associated with arthritis, rheumatoid arthritis, psoriatic arthritis, fibrous dysplasia, periodontal disease, and Paget's disease.
- endocrinopathies such as hypercortisolism, hypogonadism, primary or
- osteolysis or osteolytic bone loss resulting from cancer cell metastasis to bone are used interchangeably herein to refer to osteolysis or osteolytic bone loss resulting from cancer cell metastasis to bone.
- cancer metastasis-induced osteoclast activation is used herein to refer to the ability of cancer cells that have metastasized to bone to induce the activation of osteoclasts.
- tumor is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth.
- a tumor may be benign, pre- malignant, or malignant; malignant tumor cells are cancerous.
- Tumor cells may be solid tumor cells or leukemic tumor cells.
- tumor growth is used herein to refer to proliferation or growth by a cell or cells that comprise a tumor that leads to a corresponding increase in the size of the tumor.
- CSFIR-dependent tumor growth' is used herein to refer to the requirement of a tumor cell or cells for CSFIR- mediated function(s) in order for the tumor cell or cells to proliferate or grow.
- Treatment covers any administration or application of a therapeutic for disease in a mammal, including a human, and includes inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, partially or fully relieving the disease, or curing the disease, for example, by causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
- inhibitors refer to a decrease or cessation of any phenotypic characteristic or to the decrease or cessation in the incidence, degree, or likelihood of that characteristic.
- a "pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent that together comprise a "pharmaceutical composition" for administration to a subject.
- a pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the fonnulation.
- the phannaceutically acceptable earner is appropriate for the fonnulation employed.
- the carrier ideally is not irritable to the skin and does not cause injection site reaction.
- Anti-CSFIR antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibodies comprising the heavy chain and/ or light chain CDRs discussed herein.
- humanized antibodies that bind CSF1R are provided.
- Humanized antibodies are useful as therapeutic molecules because humanized antibodies reduce or eliminate the human immune response to non-human antibodies (such as the human anti-mouse antibody (HAMA) response), which can result in an immune response to an antibody therapeutic, and decreased effictiveness of the therapeutic.
- HAMA human anti-mouse antibody
- Nonlimiting exemplaiy humanized antibodies include Abl through Abl 6, described herein.
- Nonlimiting exemplaiy humanized antibodies also include antibodies comprising a heavy chain variable region of an antibody selected from Abl to Abl 6 and/or a light chain variable region of an antibody selected from Abl to Abl 6.
- Nonlimiting exemplaiy humanized antibodies include antibodies comprising a heavy chain variable region selected from SEQ ID NOs: 39 to 45 and/or a light chain variable region selected from SEQ ID NOs: 46 to 52.
- Exemplaiy humanized antibodies also include, but are not limited to, humanized antibodies comprising heavy chain CDRl , CDR2, and CDR3, and/or light chain CDRl , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
- a humanized anti-CSFIR antibody comprises heavy chain CDRl , CDR2, and CDR3 and/or a light chain CDRl , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
- Nonlimiting exemplaiy humanized anti-CSFIR antibodies include antibodies comprising sets of heavy chain CDRl, CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28, and 29.
- Nonlimiting exemplaiy humanized anti-CSFIR antibodies also include antibodies comprising sets of light chain CDRl , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
- Nonlimiting exemplaiy humanized anti-CSF 1 R antibodies include antibodies comprising the sets of heavy chain CDRl , CDR2, and CDR3, and light chain CDRl , CDR2, and CDR3 in Table 1 (SEQ ID NOs shown; see Table 8 for sequences). Each row of Table 1 shows the heavy chain CDRl, CDR2, and CDR3, and light chain CDRl , CDR2, and CDR3 of an exemplaiy antibody.
- a humanized anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, and wherein the antibody binds CSF1R.
- a humanized anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF1R.
- a humanized anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 11 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSF1R.
- whether a particular polypeptide is, for example, at least 95% identical to an amino acid sequence can be determined using, e.g., a computer program.
- the percentage of identity is calculated over the full length of the reference amino acid sequence.
- a humanized anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, a humanized anti-CSFIR antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDR1 discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, a humanized anti-CSFIR antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1, 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein.
- one or more of the amino acid substitutions are conservative amino acid substitutions.
- One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
- Exemplary humanized anti-CSFIR antibodies also include antibodies that compete for binding to CSF1 R with an antibody described herein.
- a humanized anti-CSFIR antibody is provided that competes for binding to CSF1R with an antibody selected from Fabs 0301 , 0302, and 031 1 ; and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
- a humanized antibody described herein comprises one or more human constant regions.
- the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
- the human light chain constant region is of an isotype selected from K and ⁇ .
- a humanized antibody described herein comprises a human IgG constant region.
- a humanized antibody described herein comprises a human IgG4 heavy chain constant region.
- a humanized antibody described herein comprises an S241P mutation in the human IgG4 constant region.
- a humanized antibody described herein comprises a human IgG4 constant region and a human ⁇ light chain.
- the choice of heavy chain constant region can determine whether or not an antibody will have effector function in vivo.
- effector function includes antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC), and can result in killing of the cell to which the antibody is bound.
- ADCC antibody-dependent cell-mediated cytotoxicity
- CDC complement-dependent cytotoxicity
- cell killing may be desirable, for example, when the antibody binds to a cell that supports the maintenance or growth of the tumor.
- Exemplaiy cells that may support the maintenance or growth of a tumor include, but are not limited to, tumor cells themselves, cells that aid in the recruitment of vasculature to the tumor, and cells that provide ligands, growth factors, or counter-receptors that support or promote tumour growth or rumour survial.
- an anti-CSFlR antibody comprising a human IgGl heavy chain or a human IgG3 heavy chain is selected.
- effector function may not be desirable.
- anti-CSFlR antibodies developed for the treatment of cancer may not be suitable for use in treatment of MS and/or RA and/or osteolysis.
- an anti-CSFlR antibody that lacks significant effector function is used in treatment of MS and/or RA and/or osteolysis.
- an anti-CSFlR antibody for treatment of MS and/or RA and/or osteolysis comprises a human IgG4 or IgG2 heavy chain constant region.
- an IgG4 constant region comprises an S241P mutation.
- An antibody may be humanized by any method.
- Nonlimiting exemplary methods of humanization include methods described, e.g., in U.S. Patent Nos. 5,530,101 ; 5,585,089; 5,693,761 ; 5,693,762; 6,180,370; Jones et al, Nature 321 : 522-525 (1986); Rieclimann et al, Nature 332: 323-27 (1988); Verhoeyen et al., Science 239: 1534-36 (1988); and U.S. Publication No. US 2009/0136500.
- a humanized antibody is an antibody in which at least one amino acid in a framework region of a non-human variable region has been replaced with the amino acid from the corresponding location in a human framework region.
- at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 1 1 , at least 12, at least 15, or at least 20 amino acids in the framework regions of a non-human variable region are replaced with an amino acid from one or more corresponding locations in one or more human framework regions.
- some of the corresponding human amino acids used for substitution are from the framework regions of different human
- one or more of the non- human amino acids may be replaced with corresponding amino acids from a human framework region of a first human antibody or encoded by a first human
- one or more of the non-human amino acids may be replaced with corresponding amino acids from a human framework region of a second human antibody or encoded by a second human immunoglobulin gene, one or more of the non-human amino acids may be replaced with corresponding amino acids from a human framework region of a third human antibody or encoded by a third human immunoglobulin gene, etc.
- all of the corresponding human amino acids being used for substitution in a single framework region for example, FR2 need not be from the same human framework. In some embodiments, however, all of the corresponding human amino acids being used for substitution are from the same human antibody or encoded by the same human immunoglobulin gene.
- an antibody is humanized by replacing one or more entire framework regions with corresponding human framework regions.
- a human framework region is selected that has the highest level of homology to the non-human framework region being replaced.
- such a humanized antibody is a CDR-grafted antibody.
- one or more framework amino acids are changed back to the corresponding amino acid in a mouse framework region.
- Such "back mutations” are made, in some embodiments, to retain one or more mouse framework amino acids that appear to contribute to the structure of one or more of the CDRs and/or that may be involved in antigen contacts and/or appear to be involved in the overall structural integrity of the antibody.
- ten or fewer, nine or fewer, eight or fewer, seven or fewer, six or fewer, five or fewer, four or fewer, three or fewer, two or fewer, one, or zero back mutations are made to the framework regions of an antibody following CDR grafting.
- a humanized antibody also comprises a human heavy chain constant region and/or a human light chain constant region.
- an anti-CSFIR antibody is a chimeric antibody.
- an anti-CSFI R antibody comprises at least one non-human variable region and at least one human constant region.
- all of the variable regions of an anti-CSFIR antibody are non-human variable regions, and all of the constant regions of an anti-CSFIR antibody are human constant regions.
- one or more variable regions of a chimeric antibody are mouse variable regions.
- the human constant region of a chimeric antibody need not be of the same isotype as the non-human constant region, if any, it replaces. Chimeric antibodies are discussed, e.g., in U.S. Patent No. 4,816,567; and Morrison et al.
- Nonlimiting exemplaiy chimeric antibodies include chimeric antibodies comprising the heavy and/or light chain variable regions of an antibody selected from 0301 , 0302, and 031 1 .
- Additional nonlimiting exemplaiy chimeric antibodies include chimeric antibodies comprising heavy chain CDR1 , CDR2, and CDR3, and/or light chain CDR1 , CDR2, and CDR3 of an antibody selected from 0301 , 0302, and 031 1.
- Nonlimiting exemplaiy chimeric anti-CSFIR antibodies include antibodies comprising the following pairs of heavy and light chain variable regions: SEQ ID NOs: 9 and 10; SEQ ID NOs: 1 1 and 12; and SEQ ID NOs: 13 and 14.
- Nonlimiting exemplaiy anti-CSFIR antibodies include antibodies comprising a set of heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 shown above in Table 1.
- a chimeric anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the antibody binds CSF1R.
- a chimeric anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF 1 R.
- a chimeric anti-CSFI R antibody comprises a heavy chain comprising a variable region sequence that is at least 90%o, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%o, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%), at least 91 %, at least 92%, at least 93% » at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%» identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSF1R.
- a chimeric anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, a chimeric anti-CSFI R antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDRl discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein.
- a chimeric anti-CSFI R antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein.
- one or more of the amino acid substitutions are conservative amino acid substitutions.
- One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
- Exemplary chimeric anti-CSFIR antibodies also include chimeric antibodies that compete for binding to CSFIR with an antibody described herein.
- a chimeric anti-CSFIR antibody is provided that competes for binding to CSFIR with an antibody selected from Fabs 0301 , 0302, and 031 1 ; and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
- a chimeric antibody described herein comprises one or more human constant regions.
- the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
- the human light chain constant region is of an isotype selected from ⁇ and ⁇ .
- a chimeric antibody described herein comprises a human IgG constant region.
- a chimeric antibody described herein comprises a human IgG4 heavy chain constant region.
- a chimeric antibody described herein comprises an S241P mutation in the human IgG4 constant region.
- a chimeric antibody described herein comprises a human IgG4 constant region and a human ⁇ light chain.
- effector function may depend on the particular method of treatment intended for an antibody.
- a chimeric anti-CSFIR antibody comprising a human IgGl heavy chain constant region or a human IgG3 heavy chain constant region is selected.
- a chimeric anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected.
- Human antibodies can be made by any suitable method.
- Nonlimiting exemplary methods include making human antibodies in transgenic mice that comprise human immunoglobulin loci. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA 90: 2551 -55 (1993); Jakobovits et al., Nature 362: 255-8 ( 1993); Lonberg et al, Nature 368: 856-9 (1994); and U.S. Patent Nos. 5,545,807; 6,713,610; 6,673,986; 6,162,963; 5,545,807; 6,300,129; 6,255,458; 5,877,397; 5,874,299; and 5,545,806.
- Nonlimiting exemplary methods also include making human antibodies using phage display libraries. See, e.g., Hoogenboom et al., J. Mol. Biol. 227: 381 -8 ( 1992); Marks et al., J. Mol. Biol. 222: 581 -97 (1991 ); and PCT
- a human anti-CSFIR antibody binds to a polypeptide having the sequence of SEQ ID NO: 1.
- Exemplary human anti-CSFIR antibodies also include antibodies that compete for binding to CSF1R with an antibody described herein.
- a human anti-CSFIR antibody is provided that competes for binding to CSF1R with an antibody selected from Fabs 0301 , 0302, and 031 1 , and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
- a human anti-CSFI antibody comprises one or more human constant regions.
- the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
- the human light chain constant region is of an isotype selected from ⁇ and ⁇ .
- a human antibody described herein comprises a human IgG constant region.
- a human antibody described herein comprises a human IgG4 heavy chain constant region.
- a human antibody described herein comprises an S241P mutation in the human IgG4 constant region.
- a human antibody described herein comprises a human IgG4 constant region and a human light chain.
- a human anti-CSFIR antibody comprising a human IgGl heavy chain constant region or a human IgG3 heavy chain constant region is selected. In some embodiments, when effector function is not desirable, a human anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected. Additional Exemplary Anti-CSFlR Antibodies
- Exemplaiy anti-CSFlR antibodies also include, but are not limited to, mouse, humanized, human, chimeric, and engineered antibodies that comprise, for example, one or more of the CDR sequences described herein.
- an anti-CSFlR antibody comprises a heavy chain variable region described herein.
- an anti-CSFlR antibody comprises a light chain variable region described herein.
- an anti-CSFlR antibody comprises a heavy chain variable region described herein and a light chain variable region described herein.
- an anti-CSFlR antibody comprises heavy chain CDR1, CDR2, and CDR3 described herein.
- an anti-CSFlR antibody comprises light chain CDR1 , CDR2, and CDR3 described herein. In some embodiments, an anti-CSFlR antibody comprises heavy chain CDR1, CDR2, and CDR3 described herein and light chain CDR1 , CDR2, and CDR3 described herein.
- an anti-CSFlR antibody comprises a heavy chain variable region of an antibody selected from Fabs 0301, 0302, and 031 1.
- Nonlimiting exemplaiy anti-CSFlR antibodies also include antibodies comprising a heavy chain variable region of an antibody selected from humanized antibodies Abl to Abl 6.
- Nonlimiting exemplaiy anti-CSFl R antibodies include antibodies comprising a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
- an anti-CSFlR antibody comprises a light chain variable region of an antibody selected from Fabs 0301 , 0302, and 31 1.
- Nonlimiting exemplaiy anti-CSFl R antibodies also include antibodies comprising a light chain variable region of an antibody selected from humanized antibodies Abl to Abl6.
- Nonlimiting exemplaiy anti-CSFlR antibodies include antibodies comprising a light chain variable region comprising a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
- an anti-CSFlR antibody comprises a heavy chain variable region and a light chain variable region of an antibody selected from Fabs 0301 , 0302, and 0311.
- Nonlimiting exemplaiy anti-CSFlR antibodies also include antibodies comprising a heavy chain variable region and a light chain variable region of an antibody selected from humanized antibodies Abl to Abl 6.
- Nonlimiting exemplaiy anti-CSFl R antibodies include antibodies comprising the following pairs of heavy and light chain variable regions: SEQ ID NOs: 9 and 10; SEQ ID NOs: 1 1 and 12; and SEQ ID NOs: 13 and 14; SEQ ID NOs: 39 and 40; SEQ ID NOs: 41 and 42; SEQ ID NOs: 43 and 44; SEQ ID NOs: 45 and 46; SEQ ID NOs: 47 and 48; SEQ ID NOs: 49 and 50; and SEQ ID NOs: 51 and 52.
- Nonlimiting exemplary anti- CSF1 R antibodies also include antibodies comprising the following pairs of heavy and light chains: SEQ ID NOs: 33 and 34; SEQ ID NOs: 35 and 36; and SEQ ID NOs: 37 and 38.
- an anti-CSFIR antibody comprises heavy chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
- Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising sets of heavy chain CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28,and 29.
- an anti-CSFIR antibody comprises light chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
- Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising sets of light chain CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
- an anti-CSFIR antibody comprises heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 of an antibody selected from Fabs 0301 , 0302, and 031 1.
- Nonlimiting exemplary anti-CSFIR antibodies include antibodies comprising the sets of heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3 shown above in Table 1.
- an anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the antibody binds CSF1R.
- an anti-CSFIR antibody comprises a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the antibody binds CSF1 R.
- an anti-CSFIR antibody comprises a heavy chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45; and a light chain comprising a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52; wherein the antibody binds CSFIR.
- an anti-CSFIR antibody comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti-CSFIR antibody comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, a heavy chain CDR3 discussed herein, a light chain CDR1 discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1, 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein.
- one or more of the amino acid substitutions are conservative amino acid substitutions.
- One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the antibody comprising the mutated CDR.
- Exemplary anti-CSFIR antibodies also include antibodies that compete for binding to CSFIR with an antibody described herein. Thus, in some embodiments
- an anti-CSFIR antibody that competes for binding to CSFIR with an antibody selected from Fabs 0301 , 0302, and 031 1 , and bivalent (i.e., having two heavy chains and two light chains) antibody versions of those Fabs.
- an antibody described herein comprises one or more human constant regions.
- the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
- the human light chain constant region is of an isotype selected from ⁇ and ⁇ .
- an antibody described herein comprises a human IgG constant region.
- an antibody described herein comprises a human IgG4 heavy chain constant region.
- an antibody described herein comprises an S241P mutation in the human IgG4 constant region.
- an antibody described herein comprises a human IgG4 constant region and a human ⁇ light chain.
- effector function may depend on the particular method of treatment intended for an antibody.
- an anti-CSFl R antibody comprising a human IgG 1 heavy chain constant region or a human IgG3 heavy chain constant region is selected.
- an anti-CSFIR antibody comprising a human IgG4 or IgG2 heavy chain constant region is selected.
- anti-CSFIR antibody heavy chain variable regions are provided.
- an anti-CSFIR antibody heavy chain variable region is a mouse variable region, a human variable region, or a humanized variable region.
- An anti-CSFIR antibody heavy chain variable region comprises a heavy chain CDR1 , FR2, CDR2, FR3, and CDR3.
- an anti- CSFIR antibody heavy chain variable region further comprises a heavy chain FR1 and/or FR4.
- Nonlimiting exemplaiy heavy chain variable regions include, but are not limited to, heavy chain variable regions having an amino acid sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45.
- an anti-CSFIR antibody heavy chain variable region comprises a CDR1 comprising a sequence selected from SEQ ID NOs: 15, 21, and 27.
- an anti-CSFIR antibody heavy chain variable region comprises a CDR2 comprising a sequence selected from SEQ ID NOs: 16, 22, and 28.
- an anti-CSFI R antibody heavy chain variable region comprises a CDR3 comprising a sequence selected from SEQ ID NOs: 17, 23, and 29.
- Nonlimiting exemplaiy heavy chain variable regions include, but are not limited to, heavy chain variable regions comprising sets of CDR1 , CDR2, and CDR3 selected from: SEQ ID NOs: 15, 16, and 17; SEQ ID NOs: 21 , 22, and 23; and SEQ ID NOs: 27, 28, and 29.
- an anti-CSFIR antibody heavy chain comprises a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 9, 1 1 , 13, and 39 to 45, wherein the heavy chain, together with a light chain, is capable of forming an antibody that binds CSFIR.
- an anti-CSFI R antibody heavy chain comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti- CSFIR antibody heavy chain comprises at least one CDR selected from a heavy chain CDR1 discussed herein, a heavy chain CDR2 discussed herein, and a heavy chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody heavy chain comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the heavy chain comprising the mutated CDR.
- a heavy chain comprises a heavy chain constant region.
- a heavy chain comprises a human heavy chain constant region.
- the human heavy chain constant region is of an isotype selected from IgA, IgG, and IgD.
- the human heavy chain constant region is an IgG constant region.
- a heavy chain comprises a human igG4 heavy chain constant region.
- the human IgG4 heavy chain constant region comprises an S241P mutation.
- a heavy chain when effector function is desirable, comprises a human IgG 1 or IgG3 heavy chain constant region. In some embodiments, when effector function is less desirable, a heavy chain comprises a human IgG4 or lgG2 heavy chain constant region.
- anti-CSFIR antibody light chain variable regions are provided.
- an anti-CSFIR antibody light chain variable region is a mouse variable region, a human variable region, or a humanized variable region.
- An anti-CSFIR antibody light chain variable region comprises a light chain CDRl , FR2, CDR2, FR3, and CDR3.
- an anti-CSFIR antibody light chain variable region further comprises a light chain FR1 and/or FR4.
- Nonlimiting exemplary light chain variable regions include light chain variable regions having an amino acid sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52.
- an anti-CSFIR antibody light chain variable region comprises a CDRl comprising a sequence selected from SEQ ID NOs: 18, 24 and 30.
- an anti-CSFIR antibody light chain variable region comprises a CDR2 comprising a sequence selected from SEQ ID NOs: 19, 25, and 31.
- an anti-CSFIR antibody light chain variable region comprises a CDR3 comprising a sequence selected from SEQ ID NOs: 20, 26, and 32.
- Nonlimiting exemplary light chain variable regions include, but are not limited to, light chain variable regions comprising sets of CDRl , CDR2, and CDR3 selected from: SEQ ID NOs: 18, 19, and 20; SEQ ID NOs: 24, 25, and 26; and SEQ ID NOs: 30, 31 , and 32.
- an anti-CSFIR antibody light chain comprises a variable region sequence that is at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NOs: 10, 12, 14, and 46 to 52, wherein the light chain, together with a heavy chain, is capable of forming an antibody that binds CSF1R.
- an anti-CSFIR antibody light chain comprises at least one of the CDRs discussed herein. That is, in some embodiments, an anti- CSFIR antibody light chain comprises at least one CDR selected from a light chain CDRl discussed herein, a light chain CDR2 discussed herein, and a light chain CDR3 discussed herein. Further, in some embodiments, an anti-CSFIR antibody light chain comprises at least one mutated CDR based on a CDR discussed herein, wherein the mutated CDR comprises 1 , 2, 3, or 4 amino acid substitutions relative to the CDR discussed herein. In some embodiments, one or more of the amino acid substitutions are conservative amino acid substitutions. One skilled in the art can select one or more suitable conservative amino acid substitutions for a particular CDR sequence, wherein the suitable conservative amino acid substitutions are not predicted to significantly alter the binding properties of the light chain comprising the mutated CDR.
- a light chain comprises a human light chain constant region.
- a human light chain constant region is selected from a human ⁇ and a human ⁇ light chain constant region.
- additional molecules that bind CSFIR are provided.
- Such molecules include, but are not limited to, non-canonical scaffolds, such as anti-calins, adnectins, ankyrin repeats, etc. See, e.g., Hosse et al., Prot. Sci. 15: 14 (2006); Fiedler, M. and Skerra, A., "Non-Antibody Scaffolds," pp.467-499 in Handbook of Therapeutic Antibodies, Dubel, S., ed., Wiley- VCH, Weinheim, Germany, 2007.
- an antibody having a structure described above binds to the CSFIR with a binding affinity (K D ) of less than 1 nM, blocks binding of CSFl and/or IL34 to CSFI R, and inhibits CSFIR phosphorylation induced by CSFl and/or IL34.
- an anti-CSFIR antibody binds to the extracellular domain of CSFIR (CSF1R-ECD).
- an anti- CSFIR antibody has a binding affinity (K D ) for CSFIR of less than 1 nM, less than 0.5 nM, less than 0.1 nM, or less than 0.05 nM.
- an anti- CSFIR antibody has a K D of between 0.01 and 1 nM, between 0.01 and 0.5 nM, between 0.01 and 0.1 nM, between 0.01 and 0.05 nM, or between 0.02 and 0.05 nM.
- an anti-CSFIR antibody blocks ligand binding to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of CSFl to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of IL34 to CSFIR. In some embodiments, an anti-CSFIR antibody blocks binding of both CSFl and IL34 to CSFIR. In some embodiments, an antibody that blocks ligand binding binds to the extracellular domain of CSFIR. An antibody is considered to "block ligand binding to CSFI R" when it reduces the amount of detectable binding of a ligand to CSF1R by at least 50%, using the assay described in Example 7.
- an antibody reduces the amount of detectable binding of a ligand to CSF1R by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 7.
- the antibody is said to block ligand binding by at least 50%, at least 60%, at least 70%, etc.
- an anti-CSFIR antibody inhibits ligand-induced CSF1 R phosphorylation. In some embodiments, an anti-CSFIR antibody inhibits CSF1 -induced CSF1R phosphoiylation. In some embodiments, an anti-CSFIR antibody inhibits IL34-induced CSF1R phosphorylation. In some embodiments, an anti-CSFIR antibody inhibits both CSF1 -induced and IL34-induced CSF1R phosphoiylation. An antibody is considered to "inhibit ligand-induced CSF1R phosphoiylation" when it reduces the amount of detectable ligand-induced CSF1R phosphoiylation by at least 50%, using the assay described in Example 6.
- an antibody reduces the amount of detectable ligand-induced CSF1R phosphoiylation by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 6.
- the antibody is said to inhibit ligand-induced CSF1R phosphorylation by at least at least 50%, at least 60%, at least 70%, etc.
- an antibody inhibits monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34.
- An antibody is considered to "inhibit monocyte proliferation and/or survival responses" when it reduces the amount of monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34 by at least 50%, using the assay described in Example 10.
- an antibody reduces the amount of monocyte proliferation and/or survival responses in the presence of CSF1 and/or IL34 by at least 60%, at least 70%, at least 80%, or at least 90%, using the assay described in Example 10.
- the antibody is said to inhibit monocyte proliferation and/or survival responses by at least at least 50%, at least 60%, at least 70%, etc.
- an anti-CSFIR antibody is conjugated to a label and/or a cytotoxic agent.
- a label is a moiety that facilitates detection of the antibody and/or facilitates detection of a molecule to which the antibody binds.
- Nonlimiting exemplary labels include, but are not limited to, radioisotopes, fluorescent groups, enzymatic groups, chemiluminescent groups, biotin, epitope tags, metal-binding tags, etc.
- One skilled in the art can select a suitable label according to the intended application.
- a cytotoxic agent is a moiety that reduces the proliferative capacity of one or more cells.
- a cell has reduced proliferative capacity when the cell becomes less able to proliferate, for example, because the cell undergoes apoptosis or otherwise dies, the cell fails to proceed through the cell cycle and/or fails to divide, the cell differentiates, etc.
- Nonlimiting exemplary cytotoxic agents include, but are not limited to, radioisotopes, toxins, and chemotherapeutic agents.
- One skilled in the art can select a suitable cytotoxic according to the intended application.
- a label and/or a cytotoxic agent is conjugated to an antibody using chemical methods in vitro.
- Nonlimiting exemplary chemical methods of conjugation are known in the art, and include services, methods and/or reagents commercially available from, e.g., Thermo Scientific Life Science Research Produces (formerly Pierce; Rockford, IL), Prozyme (Hayward, CA), SACRI Antibody Services (Calgaiy, Canada), AbD Serotec (Raleigh, NC), etc.
- the label and/or cytotoxic agent when a label and/or cytotoxic agent is a polypeptide, the label and/or cytotoxic agent can be expressed from the same expression vector with at least one antibody chain to produce a polypeptide comprising the label and/or cytotoxic agent fused to an antibody chain.
- a suitable method for conjugating a label and/or cytotoxic agent to an antibody can be selected from the same expression vector with at least one antibody chain to produce a polypeptide comprising the label and/or cytotoxic agent fused to an antibody chain.
- a leader sequence from a heterologous protein may be desirable.
- a leader sequence is selected from SEQ ID NOs: 3 and 4, which are light chain and heavy chain leader sequences, respectively.
- employing heterologous leader sequences may be advantageous in that a resulting mature polypeptide may remain unaltered as the leader sequence is removed in the ER during the secretion process.
- the addition of a heterologous leader sequence may be required to express and secrete some proteins.
- leader sequence sequences are described, e.g., in the online Leader sequence Database maintained by the Department of Biochemistry, National University of Singapore. See Choo et al, BMC Bioinformatics, 6: 249 (2005); and PCT Publication No. WO 2006/081430. Nucleic Acid Molecules Encoding Anti-CSFlR Antibodies
- nucleic acid molecules comprising polynucleotides that encode one or more chains of anti-CSFlR antibodies are provided.
- a nucleic acid molecule comprises a polynucleotide that encodes a heavy chain or a light chain of an anti-CSFlR antibody.
- a nucleic acid molecule comprises both a polynucleotide that encodes a heavy chain and a polynucleotide that encodes a light chain, of an anti-CSFlR antibody.
- a first nucleic acid molecule comprises a first polynucleotide that encodes a heavy chain and a second nucleic acid molecule comprises a second polynucleotide that encodes a light chain.
- the heavy chain and the light chain are expressed from one nucleic acid molecule, or from two separate nucleic acid molecules, as two separate polypeptides.
- a single polynucleotide encodes a single polypeptide comprising both a heavy chain and a light chain linked together.
- a polynucleotide encoding a heavy chain or light chain of an anti-CSFlR antibody comprises a nucleotide sequence that encodes a leader sequence, which, when translated, is located at the N terminus of the heavy chain or light chain.
- the leader sequence may be the native heavy or light chain leader sequence, or may be another heterologous leader sequence.
- Nucleic acid molecules may be constructed using recombinant DNA techniques conventional in the art.
- a nucleic acid molecule is an expression vector that is suitable for expression in a selected host cell.
- Vectors comprising polynucleotides that encode anti-CSFlR heavy chains and/or anti-CSFlR light chains are provided. Vectors comprising
- polynucleotides that encode anti-CSFlR heavy chains and/or anti-CSFlR light chains are also provided.
- Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc.
- a vector comprises a first polynucleotide sequence encoding a heavy chain and a second polynucleotide sequence encoding a light chain.
- the heavy chain and light chain are expressed from the vector as two separate polypeptides.
- the heavy chain and light chain are expressed as part of a single polypeptide, such as, for example, when the antibody is an scFv.
- a first vector comprises a polynucleotide that encodes a heavy chain and a second vector comprises a polynucleotide that encodes a light chain.
- the first vector and second vector are transfected into host cells in similar amounts (such as similar molar amounts or similar mass amounts).
- a mole- or mass-ratio of between 5: 1 and 1 :5 of the first vector and the second vector is transfected into host cells.
- a mass ratio of between 1 : 1 and 1 :5 for the vector encoding the heavy chain and the vector encoding the light chain is used.
- a mass ratio of 1 :2 for the vector encoding the heavy chain and the vector encoding the light chain is used.
- a vector is selected that is optimized for expression of polypeptides in CHO or CHO-derived cells, or in NSO cells.
- Exemplary such vectors are described, e.g., in Running Deer et al., Biotechnol. Prog. 20:880-889 (2004).
- a vector is chosen for in vivo expression of anti- CSF1R heavy chains and/or anti-CSFIR light chains in animals, including humans.
- expression of the polypeptide is under the control of a promoter that functions in a tissue-specific manner.
- tissue-specific promoters are described, e.g., in PCT Publication No. WO 2006/076288.
- anti-CSFIR heavy chains and/or anti-CSFIR light chains may be expressed in prokaryotic cells, such as bacterial cells; or in eukaiyotic cells, such as fungal cells (such as yeast), plant cells, insect cells, and mammalian cells. Such expression may be earned out, for example, according to procedures known in the art.
- eukaiyotic cells that may be used to express polypeptides include, but are not limited to, COS cells, including COS 7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S and DG44 cells;
- anti-CSFIR heavy chains and/or anti-CSFIR light chains may be expressed in yeast. See, e.g., U.S. Publication No. US 2006/0270045 Al .
- a particular eukaiyotic host cell is selected based on its ability to make desired post-translational
- CHO cells produce polypeptides that have a higher level of sialylation than the same polypeptide produced in 293 cells.
- Introduction of one or more nucleic acids into a desired host cell may be accomplished by any method, including but not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, etc. Nonlimiting exemplaiy methods are described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual, 3 ld ed. Cold Spring Harbor Laboratory Press (2001). Nucleic acids may be transiently or stably transfected in the desired host cells, according to any suitable method.
- one or more polypeptides may be produced in vivo in an animal that has been engineered or transfected with one or more nucleic acid molecules encoding the polypeptides, according to any suitable method.
- Anti-CSFlR antibodies may be purified by any suitable method. Such methods include, but are not limited to, the use of affinity matrices or hydrophobic interaction chromatography. Suitable affinity ligands include the CSF1R ECD and ligands that bind antibody constant regions. For example, a Protein A, Protein G, Protein A/G, or an antibody affinity column may be used to bind the constant region and to purify an anti-CSFlR antibody. Hydrophobic interactive clnOmatography, for example, a butyl or phenyl column, may also suitable for purifying some
- polypeptides Many methods of purifying polypeptides are known in the art.
- an anti-CSFlR antibody is produced in a cell-free system.
- Nonlimiting exemplary cell-free systems are described, e.g., in
- Antibodies of the invention, and compositions comprising antibodies of the invention are provided for use in methods of treatment for humans or animals. Methods of treating disease comprising administering anti-CSRIR antibodies are also provided. Nonlimiting exemplaiy diseases that can be treated with anti-CSFlR antibodies include, but are not limited to, RA, MS, cancer, metastasis-induced osteolytic bone loss, osteolytic disorders, and hypercalcemia-induced bone loss. [0166] In some embodiments, methods of treating inflammatory conditions comprising administering an anti-CSFIR antibody are provided. In some embodiments,
- an inflammatory condition is selected from psoriasis, SLE (lupus), COPD, atopic demiatitis, and atherosclerosis, macrophage activation syndrome, and histiocytosis X.
- methods of treating an inflammatory condition comprising administering an anti-CSFIR antibody are provided, wherein the inflammatory condition is selected from: proliferative vascular disease, acute respiratory distress syndrome, cytokine -mediated toxicity, interleukin-2 toxicity, appendicitis, peptic, gastric and duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, inflammatory bowel disease, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatos
- methods of treating cancer comprising administering an anti-CSFIR antibody.
- the cancer is a CSF1 -secreting cancer.
- the cancer is one or more cancers selected from breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cervical cancer, and ovarian cancer.
- an anti-CSFI R antibody is useful for treating one or more cancers selected from lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma.
- anti-CSFIR antibodies may be administered in vivo by various routes, including, but not limited to, oral, intra-arterial, parenteral, intranasal, intramuscular, intracardiac, intraventricular, intratracheal, buccal, rectal, intraperitoneal, intradermal, topical, transdermal, and intrathecal, or otherwise by implantation or inhalation.
- the subject compositions may be formulated into preparations in solid, semi-solid, liquid, or gaseous forms; including, but not limited to, tablets, capsules, powders, granules, ointments, solutions, suppositories, enemas, injections, inhalants, and aerosols.
- a nucleic acid molecule encoding an anti-CSFI R antibody may be coated onto gold microparticles and delivered intradermally by a particle bombardment device, or "gene gun,” as described in the literature (see, e.g., Tang et al., Nature 356: 152-154 (1992)).
- a particle bombardment device or "gene gun”
- the appropriate formulation and route of administration may be selected according to the intended application.
- compositions comprising anti-CSFIR antibodies are provided in formulations with a wide variety of pharmaceutically acceptable earners (see, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Phis, 20th ed. (2003); Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7 th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3 rd ed., Pharmaceutical Press (2000)).
- Various pharmaceutically acceptable earners which include vehicles, adjuvants, and diluents, are available.
- Non-limiting exemplary earners include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
- compositions comprising anti-CSFIR antibodies may be formulated for injection, including subcutaneous administration, by dissolving, suspending, or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids, or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preserva tives.
- the compositions may be formulated for inhalation, for example, using pressurized acceptable propellants such as
- compositions may also be formulated, in various embodiments, into sustained release microcapsules, such as with biodegradable or non-biodegradable polymers.
- a non-limiting exemplary biodegradable formulation includes poly lactic acid-glycolic acid polymer.
- a non- limiting exemplary non-biodegradable formulation includes a polyglycerin fatty acid ester. Certain methods of making such fomiulations are described, for example, in EP 1 125 584 Al .
- compositions comprising an anti-CSFI R antibody, with or without one or more additional agents.
- a unit dosage is supplied in single-use prefilled syringe for injection.
- the composition contained in the unit dosage may comprise saline, sucrose, or the like; a buffer, such as phosphate, or the like; and/or be formulated within a stable and effective pH range.
- the composition may be provided as a lyophilized powder that may be reconstituted upon addition of an appropriate liquid, for example, sterile water.
- the composition comprises one or more substances that inhibit protein aggregation, including, but not limited to, sucrose and arginine.
- a composition of the invention comprises heparin and/or a proteoglycan.
- compositions are administered in an amount effective for treatment or prophylaxis of the specific indication.
- the therapeutically effective amount is typically dependent on the weight of the subject being treated, his or her physical or health condition, the extensiveness of the condition to be treated, or the age of the subject being treated.
- anti-CSFIR antibodies may be administered in an amount in the range of about 10 ⁇ g/kg body weight to about 100 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 50 fig/kg body weight to about 5 mg/kg body weight per dose. In some embodiments, anti-CSFIR antibodies may be administered in an amount in the range of about 100 g kg body weight to about 10 mg/kg body weight per dose.
- anti-CSFIR antibodies may be administered in an amount in the range of about 100 ng/kg body weight to about 20 mg/kg body weight per dose. In some embodiments, anti-CSFI R antibodies may be administered in an amount in the range of about 0.5 mg/kg body weight to about 20 mg/kg body weight per dose.
- the anti-CSFIR antibody compositions may be administered as needed to subjects. Detemiination of the frequency of administration may be made by persons skilled in the art, such as an attending physician based on considerations of the condition being treated, age of the subject being treated, severity of the condition being treated, general state of health of the subject being treated and the like.
- an effective dose of an anti-CSFIR antibody is administered to a subject one or more times.
- an effective dose of an anti- CSFIR antibody is administered to the subject once a month, more than once a month, such as, for example, eveiy two months or eveiy three months.
- an effective dose of an anti-CSFIR antibody is administered less than once a month, such as, for example, eveiy two weeks or eveiy week.
- An effective dose of an anti-CSFIR antibody is administered to the subject at least once.
- the effective dose of an anti-CSFIR antibody may be administered multiple times, including for periods of at least a month, at least six months, or at least a year.
- Anti-CSFIR antibodies may be administered alone or with other modes of treatment. They may be provided before, substantially contemporaneous with, or after other modes of treatment, for example, surgery, chemotherapy, radiation therapy, or the administration of a biologic, such as another therapeutic antibody.
- anti-CSFI R antibodies may be administered with other therapeutic agents, for example, methotrexate, anti-TNF agents such as
- glucocorticoids such as prednisone
- anti-CSFIR antibodies may be administered with other therapeutic agents, for example, interferon alpha; interferon beta; prednisone; anti-alpha4 integrin antibodies such as Tysabri; anti-CD20 antibodies such as Rituxan; FTY720 (Fingolimod); and Cladribine (Leustatin).
- Example 1 Selection of Fabs that bind CSFIR extracellular domain (ECD)
- mice were immunized with a human CSFIR extracellular domain Fc fusion, hCSFI R ECD.506-Fc (SEQ ID NO: 6). Spleens from immunized mice were isolated, and a Fab phage display library was created from the spenocytes. Fab- expressing phage were selected for binding to human CSFIR ECD. Fabs from positive-binding phage were expressed and purified from bacteria. A total of 1056 Fab clones were selected for further analysis.
- Fabs were screened for the ability to bind human CSFIR ECD, block binding of human CSFl to human CSFIR ECD, and block binding of human IL34 to human CSFI R ECD. Sequence analysis and clusertering of the Fabs that were selected from that screen was then performed and certain unique Fabs were selected.
- the unique Fabs were further analyzed for the ability to bind human CSFIR ECD, the ability to bind cynomolgus CSFIR ECD, and the ability to bind mouse CSFIR ECD.
- the Fabs were also analyzed for the ability to block human CSFl binding to human CSFIR ECD and the ability to block human IL34 binding to human CSFIR ECD, and the ability to inliibit ligand-induced CSFIR phosphorylation in the presence of CSFl or IL34. (Data not shown.)
- Example 2 Reformatting of anti-CSFIR Fabs to make chimeric antibodies
- Fab VH regions cloned into and expressed from vector pTT5 (Biotechnology Research Institute, Montreal, Canada; and National Research Research Council of Canada, Ottawa, Canada) modified to contain a mouse IgH leader sequence (SEQ ID NO: 4) and a human IgG4 heavy chain constant region with the S241P mutation (SEQ ID NO: 94).
- Fab VL regions were cloned into and expressed from vector pTT5 modified to contain a mouse IgK leader sequence (SEQ ID NO: 3) and a human IgK light chain constant region (SEQ ID NO: 95). Fab V regions were inserted in such a way as not to introduce non-antibody derived amino acid sequences into the final proteins.
- the chimeric antibodies were transiently expressed and purified substantially as described below in Example 5.
- the 1 1 chimeric antibodies were assayed for binding to human, cynoinolgus, and mouse CSFI R ECD.
- the chimeric antibodies were also assayed for the ability to block binding of human CSF1 to human CSF ] R ECD, the ability to block binding of human IL34 to human CSFIR ECD, the ability to block binding of human CSF1 to cynomolgus CSFIR ECD, and the ability to inhibit ligand-induced CSFI R phosphorylation in the presence of CSF1 or IL34.
- the chimeric antibodies were further assayed for binding to CSFIR on the surface of cells.
- the chimeric antibodies were assayed to confirm that they do not induce CSFI R phosphorylation in the absence of ligand. (Data not shown.)
- chimeric anti-CSFIR antibodies 0301 , 0302, and 031 1 were selected for humanization.
- the antibodies were humanized by changing certain amino acid residues in the framework regions of the heavy and light chain variable regions.
- the criteria used for humanization were as described previously, e.g., in U.S. Publication No. US 2009/0136500.
- cAb 0301 three humanized heavy chain variable regions and two humanized light chain variable regions were designed, for a total of six humanized antibodies, Abl to Ab6.
- cAb 0302 two humanized heavy chain variable regions and three humanized light chain variable regions were designed, for a total of six humanized antibodies, Ab7 to Abl 2.
- cAb 0311 two humanized heavy chain variable regions and two humanized light chain variable regions were designed, for a total of four humanized antibodies, Abl 3 to Abl 6.
- Table 8 shows the full sequences for the humanized heavy chains and humanized light chains of antibodies Abl to Abl 6. The name and SEQ ID NOs of the humanized heavy chain and humanized light chain of each of those antibodies is shown in Table 2.
- Example 5 Humanized auti-CSFlR antibodies bind to human and cynomolgus CSF1R ECD, but not to mouse CSF1R ECD
- the 16 humanized antibodies were transiently expressed in CHO cells, as follows. CHO-3E7 cells were co-transfected with individual heavy and light chain expression plasmids at a mass ratio of 1 heavy chain plasmid to 2 light chain plasmids using polyethyleneinimine (PEI) at a DNA:PEI ratio of 1 :5. Total DNA used per transfection was 1.5 ⁇ g/ml of cells.
- PEI polyethyleneinimine
- Humanized antibodies were purified from transfected cell supematants using HiTrap Protein A HP columns (GE Healthcare) followed by further purification using Phenyl HP columns (GE Healthcare).
- Antibody containing supematants were loaded onto HiTrap Protein A HP columns pre-equilibrated with PBS/0.5M NaCl.
- Antibody loaded columns were washed with 10 column volumes PBS/0.5M NaCl, and eluted with a mixed linear-step gradient of 0.1 M Glycine, pH 2.7/ 0.5 M NaCl directly into 100 ul of 1M Tris buffer, pH 8.0.
- Antibody containing eluates were dialyzed against PBS, after which 2.4 M (NH 4 ) 2 S0 4 (Sigma) was added to achieve a conductivity equal to that of 1 OmM Potassium Phosphate pH7.0/l .2 M (NH 4 ) 2 S0 4 .
- Antibodies were then loaded on 1 ml Phenyl HP columns (GE Healthcare) pre- equilibrated with lOmM Potassium Phosphate pH7.0/1.2 M (NH 4 ) 2 S0 4 .
- Antibody loaded columns were washed with 15 column volumes lOmM Potassium Phosphate pH7.0/l .2 M (NH 4 ) 2 S0 , and eluted with a 20 column volume gradient of 10 niM Potassium Phosphate, pH 7.0.
- Antibody containing fractions were pooled and dialyzed against PBS.
- humanized antibodies along with their parental chimeric antibodies (cAbs), were assayed for binding to human, cynomolgus, and mouse CSF1R ECD, as follows.
- cynomolgus CSFIR ECD was determined as described above for human CSFIR, except the wells of the clear-bottom ELISA plates were coated overnight with 2 ⁇ g/ml recombinant cynoCSFIR ECD-Fc (FivePrime Therapeutics, SEQ ID NO: 8, but without the 19 amino acid leader sequence).
- Table 3 shows the EC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software) for each humanized antibody binding to human CSFIR ECD and cynomolgus CSFIR ECD. Because none of the chimeric antibodies detectably bound to mouse CSFIR ECD, an EC50 could not be calculated from that data. Table 3 also includes the calculated EC50s for the parental chimeric antibodies.
- Example 6 Humanized anti-CSFIR antibodies inhibit ligaiid-induced CSFIR phosphorylation
- CSFIR is phosphorylated in the presence of ligands CSFl or IL34.
- CSFIR SEQ ID NO: 2
- CSFIR SEQ ID NO: 2
- CSF1R (SEQ ID NO: 2)-transfected CHO cells were incubated with 0.002 to 8 ⁇ ig/ml of each humanized antibody or a parental chimeric antibody for 60 min on ice, after which 3.3 nM of human IL34 (FivePrime Therapeutics; SEQ ID NO: 68) was added to the cells. The cells were incubated for 3 minutes at 37°C, and then lysed by addition of 1/1 Ox volume of lOx cell lysis buffer (Cell Signaling
- the amount of phosphorylated CSF1R in the cell lysates was quantified using a human phospho-M-CSF R ELISA kit (R&D Systems) according to the manufacturer's instructions.
- Example 7 Humanized anti-CSFIR antibodies block human CSF1 and human IL34 binding to human and cynomolgous CSF1R
- the humanized antibodies along with the parental chimeric antibodies (cAbs), were tested for their ability to block human CSF1 binding to human and cynomolgus CSF1R ECD, as follows.
- Recombinant Human CSF1 (M-CSF; R&D Systems) was biotinylated using an NH2-Biotin Labeling Kit (Dojindo Molecular Technologies).
- M-CSF Recombinant Human CSF1
- NH2-Biotin Labeling Kit Dojindo Molecular Technologies
- One hundred ⁇ of 1 ⁇ g/ml biotinylated CSF1 in PBST/0.1 % BSA was added to the wells of Reacti- Bind Streptavidin coated plates (Pierce) pre-blocked with SuperBlock blocking buffer (Pierce) according to the manufacturer's instructions.
- the humanized antibodies were tested for their ability to block human IL34 binding to human CSF1R ECD.
- the blocking activity of each humanized antibody was determined as described above for blocking of CSF1 , except recombinant human IL34 (FivePrime Therapeutics; SEQ ID NO: 68) was biotinylated using an NH2-Biotin Labeling Kit (Dojindo Molecular Technologies), and then 100 ⁇ of 1 ⁇ g ml biotinylated recombinant IL34 in PBST/0.1 % BSA was added to the wells of Reacti-Bind Streptavidin coated plates (Pierce) pre-blocked with SuperBlock blocking buffer (Pierce) according to the manufacturer's instructions.
- Table 4 shows the IC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software), for inhibition of ligand-induced CSFI R phosphoiylation by each humanized antibody.
- Table 4 also shows the IC50, calculated using the non-linear regression (curve-fit) analysis algorithm of the GraphPad Prism software (GraphPad Software), for blocking of ligand binding to CSF I R ECD by each humanized antibody.
- Table 4 shows the number of amino acids in the framework regions of the light and heavy chain of each humanized antibody that were back-mutated to the corresponding mouse amino acid residue.
- humanized antibody h0301 LlHl has one amino acid in a light chain framework region that was back-mutated to the mouse amino acid, and one amino acid in the heavy chain framework regions that was back- mutated to the mouse amino acid.
- the back-mutated amino acid in the light chain framework is at position 1 in framework 1
- the back- mutated amino acid in the heavy chain is at position 71 in framework 3 according to Kabat numbering (see Figure I B).
- the k a , 13 ⁇ 4, and 3 ⁇ 4 for binding to human CSF1R ECD was determined for each of the humanized antibodies as follows.
- Binding kinetics of anti-CSFIR humanized antibodies to CSF1R ECD was determined using Biacore T100 Surface Plasmon Resononance (SPR) (GE Healthcare Life Sciences, Piscataway, NY). Each of the humanized anti-CSFIR antibodies was captured on a CM5 sensor chip immobilized with anti-Human IgG antibody using the Human antibody capture kit (GE Healthcare Life Sciences, Piscataway, NY) at 150RU so that the Rmax value for hCSFIR ECD.506 (SEQ ID NO: 5) binding was 100RU. Rmax values of less than 150RU are recommended for accurately determining kinetic values.
- SPR Surface Plasmon Resononance
- hCSFIR ECD.506 was injected at six concentrations (90 nM, 30 nM, 10 nM, 3.33 nM, 1.1 1 nM, and 0 nM) for 2 minutes and dissociation was observed for 5 minutes to detemiine humanized antibody/hCSFIR ECD binding kinetic parameters.
- the association constant, dissociation constant, affinity, and binding capacity of each of the Fabs for human CSF1 R ECD was calculated using the Biacore T100 Evaluation software package using the 1 : 1 binding model.
- huAb 0302-L0H2 3.40 x 106 1.79 x 10-03 0.53 huAb 0302-Ll H2 2.71 x 106 1.53 x 10-03 0.56 huAb 0302-L2H2 1.84 x 106 8.40 x 10-04 0.46 huAb 031 1 -L0H 1 1.22 x 106 5.40 x 10-04 0.44 huAb 031 1 -LI HI 1.32 x 106 6.64 x 10-04 0.50 huAb 031 1 -L0H2 1.34 x 106 4.73 x 10-04 0.35 huAb 031 1 -LlH2 1.51 x 106 6.09 x 10-04 0.40
- Example 10 Humanized anti-CSFIR antibodies block ligand-induced proliferation/survival responses of primary human monocytes
- Humanized antibodies 0301-L0H0, 0301-LlHO, and 0311-LOHl were tested for their ability to block ligand-induced monocyte proliferation/survival responses as follows.
- Human peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor blood by centrifugation onto a Ficoll-Paque cushion (GE).
- Peripheral blood monocytes were subsequently isoated from the recovered PBMC fraction by centrifugation onto a 48.5% PercollTM cushion (GE Healthcare Bio-Sciences). After recovery from the PercollTM cushion, the purified peripheral blood monocytes were stimuated with 162 pM recombinant human CSF1 or 1.6 nM recombinant human IL34 (both from R&D Systems) in the presence or absence of serial dilutions of humanised antibody 0301 -LOHO, humanised antibody 0301 -LI HO, or humanised antibody 0311-LOHl .
- Example 11 Humanized anti-CSFlR antibodies do not directly stimulate primary human monocyte proliferation or survival responses
- Humanized antibodies 0301 -L0H0, 0301 -LI HO, and 031 1 -L0H1 were tested for their ability to directly stimulate primary monocyte proliferation and/or survival, as follows.
- Human peripheral blood monocytes were isolated as described in Example 10. Serial dilutions of humanised antibody 0301-LOHO, humanised antibody 0301-L1H0, or humanised antibody 031 1 -LOHl were added to the monocytes in the absence of stimulation either by exogenous CSF1 or by exogenous IL34. After incubation at 37°C for 48 hours, relative ATP content of each individual cuture was assessed using CellTiter Glo® reagent (Promega) as in Example 10. The experiment was earned out on peripheral blood monocytes from three different donors.
- Table 8 provides certain sequences discussed herein. All polypeptide and antibody sequences are shown without leader sequences, unless otherwise indicated.
- NLKVMVEAYP GLQGFNWTYL GPFSDHQPEP KLANATTKDT YRHTFTLSLP
- RLKPSEAGRY SFLARNPGGW RALTFELTLR YPPEVSVIWT FINGSGTLLC AASGYPQPNV TWLQCSGHTD RCDEAQVLQV WDDPYPEVLS QEPFHKVTVQ SLLTVETLEH NQTYECRAHN SVGSGSWAFI PISAGAH
- DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
- EIQLQQSGPE LVRPGASVKM SCKASGYTFS DFNIHWVKQK PGQGLEWIGY INPYTDVTVY NEKFKGKATL TSDRSSSTAY MDLSSLTSED SAVYYCASYF DGTFDYALDY WGQGTSITVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSW TVPSSSLGTK
- EIQLQQSGPD LMKPGASVKM SCKASGYIFT DYNMHWVKQN QGKSLEWMGE INPNNGVWY NQKFKGTTTL TVDKSSSTAY MDLHSLTSED SAVYYCTRAL YHSNFGWYFD SWGKGTTLTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT
- DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK DIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSHMNWY QQKPGQPPKL LIYTASNLES GIPARFSGSG SGADFTLTIH PVEEEDAATY YCQQGNEDPW
- DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
- DTLMISRTPE VTCVWDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
- DTLMISRTPE VTCWVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRWSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011248083A AU2011248083B2 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind CSF1R |
NZ603193A NZ603193A (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
DK11778283.9T DK2566517T3 (en) | 2010-05-04 | 2011-05-04 | ANTIBODIES THAT BIND CSF1R |
EP11778283.9A EP2566517B1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
PL11778283T PL2566517T3 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
RS20190025A RS58211B1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
LTEP11778283.9T LT2566517T (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
JP2013509230A JP6008842B2 (en) | 2010-05-04 | 2011-05-04 | Antibody binding to CSF1R |
ES11778283T ES2706412T3 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind to CSF1R |
BR112012027994-7A BR112012027994B1 (en) | 2010-05-04 | 2011-05-04 | ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF AN ANTIBODY |
SG2012079133A SG185035A1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
KR1020207011504A KR20200044999A (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
EA201291161A EA036336B1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
KR1020127031635A KR101838698B1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
KR1020187006772A KR102105776B1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
EP18151214.6A EP3357510B1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
CA2797399A CA2797399C (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
CN201180022404.5A CN103179985B (en) | 2010-05-04 | 2011-05-04 | Antibody in conjunction with CSF1R |
SI201131627T SI2566517T1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
MX2015007635A MX355418B (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r. |
EP20182161.8A EP3943154A1 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
MX2012012790A MX2012012790A (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r. |
IL222629A IL222629B (en) | 2010-05-04 | 2012-10-23 | Antibodies that bind csf1r |
AU2015202477A AU2015202477C1 (en) | 2010-05-04 | 2015-05-07 | Antibodies that bind csf1r |
AU2016262662A AU2016262662B2 (en) | 2010-05-04 | 2016-11-22 | Antibodies that bind csf1r |
IL255524A IL255524B (en) | 2010-05-04 | 2017-11-08 | Antibodies that bind csf1r |
IL257712A IL257712B (en) | 2010-05-04 | 2018-02-25 | Antibodies that bind csf1r |
HRP20190047TT HRP20190047T1 (en) | 2010-05-04 | 2019-01-07 | Antibodies that bind csf1r |
CY191100027T CY1121102T1 (en) | 2010-05-04 | 2019-01-14 | ANTIBODIES THAT BIND CSF1R |
AU2019200691A AU2019200691B2 (en) | 2010-05-04 | 2019-02-01 | Antibodies that bind CSF1R |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33117710P | 2010-05-04 | 2010-05-04 | |
US61/331,177 | 2010-05-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011140249A2 true WO2011140249A2 (en) | 2011-11-10 |
WO2011140249A3 WO2011140249A3 (en) | 2013-08-15 |
Family
ID=44902080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/035231 WO2011140249A2 (en) | 2010-05-04 | 2011-05-04 | Antibodies that bind csf1r |
Country Status (26)
Country | Link |
---|---|
US (8) | US8206715B2 (en) |
EP (3) | EP3357510B1 (en) |
JP (6) | JP6008842B2 (en) |
KR (3) | KR101838698B1 (en) |
CN (4) | CN112480256A (en) |
AU (4) | AU2011248083B2 (en) |
BR (1) | BR112012027994B1 (en) |
CA (1) | CA2797399C (en) |
CY (1) | CY1121102T1 (en) |
DK (1) | DK2566517T3 (en) |
EA (1) | EA036336B1 (en) |
ES (2) | ES2706412T3 (en) |
HR (1) | HRP20190047T1 (en) |
HU (1) | HUE042898T2 (en) |
IL (3) | IL222629B (en) |
LT (1) | LT2566517T (en) |
MX (2) | MX355418B (en) |
NZ (3) | NZ626610A (en) |
PL (1) | PL2566517T3 (en) |
PT (1) | PT2566517T (en) |
RS (1) | RS58211B1 (en) |
SG (3) | SG10201604798SA (en) |
SI (1) | SI2566517T1 (en) |
TR (1) | TR201900368T4 (en) |
TW (5) | TWI595008B (en) |
WO (1) | WO2011140249A2 (en) |
Cited By (217)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013169264A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US8747845B2 (en) | 2010-05-04 | 2014-06-10 | Five Prime Therapeutics, Inc. | Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
CN104093740A (en) * | 2012-02-06 | 2014-10-08 | 弗·哈夫曼-拉罗切有限公司 | Compositions and methods for using CSF1R inhibitors |
WO2015028455A1 (en) * | 2013-08-30 | 2015-03-05 | Ucb Biopharma Sprl | Antibodies |
US8999327B2 (en) | 2009-12-10 | 2015-04-07 | Hoffman-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
JP2015514811A (en) * | 2012-04-26 | 2015-05-21 | バクシネックス インコーポレーティッド | Fusion protein to facilitate the selection of cells infected with specific immunoglobulin transgenic vaccinia virus |
WO2015100282A1 (en) | 2013-12-24 | 2015-07-02 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
US9192667B2 (en) | 2013-04-22 | 2015-11-24 | Hoffmann-La Roche Inc. | Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist |
JP2015533787A (en) * | 2012-08-31 | 2015-11-26 | ファイブ プライム セラピューティックス インコーポレイテッド | Method of treating a condition with an antibody that binds colony stimulating factor 1 receptor (CSF1R) |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
WO2015200089A1 (en) | 2014-06-23 | 2015-12-30 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US9243066B2 (en) | 2011-07-18 | 2016-01-26 | University Of Melbourne | Use of M-CSF antibodies in the treatment of osteoarthritis or pain |
WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
WO2016106266A1 (en) | 2014-12-22 | 2016-06-30 | Bristol-Myers Squibb Company | TGFβ RECEPTOR ANTAGONISTS |
WO2016106180A1 (en) | 2014-12-22 | 2016-06-30 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
JPWO2014054820A1 (en) * | 2012-10-03 | 2016-08-25 | 株式会社カイオム・バイオサイエンス | Anti-human Dlk-1 antibody having antitumor activity in vivo |
WO2016140884A1 (en) | 2015-03-02 | 2016-09-09 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
WO2016161269A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
WO2016168149A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2016183118A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016183115A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
WO2017019757A1 (en) | 2015-07-28 | 2017-02-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
US9598422B2 (en) | 2014-11-05 | 2017-03-21 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9643972B2 (en) | 2014-11-05 | 2017-05-09 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017106291A1 (en) | 2015-12-15 | 2017-06-22 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
JP2017125040A (en) * | 2017-02-28 | 2017-07-20 | ファイブ プライム セラピューティックス インコーポレイテッド | Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
US9856316B2 (en) | 2013-04-12 | 2018-01-02 | Morphosys Ag | Antibodies targeting M-CSF |
WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2018136700A1 (en) | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
WO2018187613A2 (en) | 2017-04-07 | 2018-10-11 | Bristol-Myers Squibb Company | Anti-icos agonist antibodies and uses thereof |
WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
WO2018213377A1 (en) | 2017-05-17 | 2018-11-22 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
WO2019006283A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of ido inhibitors |
WO2019023459A1 (en) | 2017-07-28 | 2019-01-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046500A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019055537A1 (en) | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019079261A1 (en) | 2017-10-16 | 2019-04-25 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
JP2019089840A (en) * | 2019-02-22 | 2019-06-13 | ファイブ プライム セラピューティックス インコーポレイテッド | Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019133747A1 (en) | 2017-12-27 | 2019-07-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
WO2019147982A1 (en) | 2018-01-26 | 2019-08-01 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
WO2019160884A1 (en) | 2018-02-13 | 2019-08-22 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
WO2019166596A1 (en) | 2018-02-28 | 2019-09-06 | Ultrahuman Twelve Limited | Csf1r binding agents |
WO2019173587A1 (en) | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
WO2019191295A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
WO2019200256A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
WO2019204257A1 (en) | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
WO2019243832A1 (en) | 2018-06-22 | 2019-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
WO2020006016A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
WO2020069372A1 (en) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10640765B2 (en) | 2016-08-02 | 2020-05-05 | Vaccinex, Inc. | Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10696650B2 (en) | 2017-08-17 | 2020-06-30 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
US10793563B2 (en) | 2018-01-29 | 2020-10-06 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
EP3733698A1 (en) | 2015-09-23 | 2020-11-04 | Bristol-Myers Squibb Company | Glypican-3 binding fibronectin based scafflold molecules |
WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
US10874743B2 (en) | 2017-12-26 | 2020-12-29 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021026179A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2021041588A1 (en) | 2019-08-28 | 2021-03-04 | Bristol-Myers Squibb Company | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2021058718A1 (en) | 2019-09-26 | 2021-04-01 | Roche Diagnostics Gmbh | Anti-csf-1r antibody |
US10982001B2 (en) | 2012-05-11 | 2021-04-20 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10988477B2 (en) | 2018-01-29 | 2021-04-27 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
WO2021101919A1 (en) | 2019-11-19 | 2021-05-27 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
US11021481B2 (en) | 2019-09-13 | 2021-06-01 | Nimbus Saturn, Inc. | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists |
WO2021108288A1 (en) | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
WO2021133748A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinolinonyl piperazine compounds useful as t cell activators |
WO2021133749A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as t cell activators |
WO2021133751A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
WO2021133750A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted bicyclic piperidine derivatives useful as t cell activators |
WO2021133752A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted heteroaryl compounds useful as t cell activators |
WO2021129673A1 (en) * | 2019-12-24 | 2021-07-01 | Adagene (Suzhou) Limited | Anti-csf1r molecules and use thereof |
AU2019204985B2 (en) * | 2012-05-11 | 2021-07-15 | Five Prime Therapeutics, Inc. | Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
WO2021139682A1 (en) | 2020-01-07 | 2021-07-15 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2021178488A1 (en) | 2020-03-03 | 2021-09-10 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
US11117889B1 (en) | 2018-11-30 | 2021-09-14 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
WO2021188769A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
WO2021194914A1 (en) | 2020-03-23 | 2021-09-30 | Bristol-Myers Squibb Company | Substituted oxoisoindoline compounds for the treatment of cancer |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021247591A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
WO2021257643A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2022038158A1 (en) | 2020-08-17 | 2022-02-24 | Bicycletx Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US11337970B2 (en) | 2016-08-26 | 2022-05-24 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022120354A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
WO2022136255A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022136266A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022148979A1 (en) | 2021-01-11 | 2022-07-14 | Bicycletx Limited | Methods for treating cancer |
WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
WO2022167457A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
WO2022167445A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022216573A1 (en) | 2021-04-05 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
US11512133B2 (en) | 2013-09-12 | 2022-11-29 | Hoffmann-La Roche Inc. | Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2023028235A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
US11607453B2 (en) | 2017-05-12 | 2023-03-21 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
US11623932B2 (en) | 2017-09-22 | 2023-04-11 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2023061930A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
US11685750B2 (en) | 2020-06-03 | 2023-06-27 | Kymera Therapeutics, Inc. | Crystalline forms of IRAK degraders |
US11707457B2 (en) | 2019-12-17 | 2023-07-25 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
EP4249066A2 (en) | 2014-12-23 | 2023-09-27 | Bristol-Myers Squibb Company | Antibodies to tigit |
US11773103B2 (en) | 2021-02-15 | 2023-10-03 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
US11857535B2 (en) | 2020-07-30 | 2024-01-02 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
US11932624B2 (en) | 2020-03-19 | 2024-03-19 | Kymera Therapeutics, Inc. | MDM2 degraders and uses thereof |
WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
WO2024086718A1 (en) | 2022-10-20 | 2024-04-25 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
US11976125B2 (en) | 2017-10-13 | 2024-05-07 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
TWI844756B (en) | 2019-12-24 | 2024-06-11 | 大陸商寶船生物醫藥科技(上海)有限公司 | Anti-csf1r molecules and use thereof |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
KR102684038B1 (en) * | 2015-02-09 | 2024-07-10 | 유씨비 바이오파마 에스알엘 | pharmaceutical preparations |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2413087T3 (en) | 2006-06-13 | 2013-07-15 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for the diagnosis and treatment of cancer |
EP2125887A4 (en) | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
EP2899211A1 (en) | 2008-07-08 | 2015-07-29 | OncoMed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US9161968B2 (en) * | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
CN109022465B (en) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | Polypeptide constructs and uses thereof |
EP2961421A1 (en) * | 2013-02-28 | 2016-01-06 | University Court of the University of Edinburgh | Csf1 therapeutics |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
EP3079708A4 (en) | 2013-12-09 | 2017-08-30 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US20170023576A1 (en) * | 2014-04-04 | 2017-01-26 | Oncomed Pharmaceuticals, Inc. | Notch3 antibodies and uses thereof |
JP6851322B2 (en) * | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | How to treat neurological disorders |
CN113855804A (en) | 2015-06-15 | 2021-12-31 | 小利兰·斯坦福大学托管委员会 | Methods and compositions for treating aging-related disorders |
JP6621252B2 (en) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | Treatment resistance reducing agent for treatment resistant cancer |
KR102677543B1 (en) * | 2015-09-16 | 2024-06-24 | 아블렉시스, 엘엘씨 | anti-CD115 antibody |
EP4353320A3 (en) | 2016-04-28 | 2024-05-15 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
AU2018237300A1 (en) | 2017-03-23 | 2019-10-17 | The Trustees Of The University Of Pennsylvania | Anti-C5a antibodies and uses thereof |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
MA48480A (en) | 2017-04-26 | 2020-03-04 | Alkahest Inc | DOSAGE SCHEDULE FOR THE TREATMENT OF COGNITIVE AND MOTOR DEFICIENCIES WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS |
CR20200138A (en) | 2017-08-25 | 2020-06-14 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
WO2019080889A1 (en) * | 2017-10-26 | 2019-05-02 | 江苏恒瑞医药股份有限公司 | Anti-csf-1r antibody, antigen-binding fragment thereof and pharmaceutical use thereof |
CN108276495B (en) * | 2018-01-24 | 2022-03-18 | 博生吉医药科技(苏州)有限公司 | NK92MI cell and T cell modified by targeted CSF1R chimeric antigen receptor and preparation method and application thereof |
CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
WO2019204604A1 (en) * | 2018-04-19 | 2019-10-24 | The Board Of Trustees Of The University Of Illinois | Methods and compositions of inhibiting csf1r for treating allergic inflammation |
CN108948199B (en) * | 2018-07-18 | 2019-06-21 | 博奥信生物技术(南京)有限公司 | Anti-human CSF-1R monoclonal antibody and application thereof |
CN108948198B (en) * | 2018-07-18 | 2020-09-01 | 博奥信生物技术(南京)有限公司 | Anti-human CSF-1R monoclonal antibody and application thereof |
CN109053887B (en) * | 2018-07-18 | 2019-07-23 | 博奥信生物技术(南京)有限公司 | A kind of anti-human CSF-1R monoclonal antibody and purposes |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
IL282227B1 (en) | 2018-10-26 | 2024-04-01 | Alkahest Inc | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
CN113301960A (en) | 2018-12-13 | 2021-08-24 | 财团法人生物技术开发中心 | Anti-human CSF-1R antibodies and uses thereof |
WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
CN112300277A (en) * | 2019-07-25 | 2021-02-02 | 苏州丁孚靶点生物技术有限公司 | CSF1R antibodies, genes, vectors, host cells and CSF1R antagonists |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
WO2009112245A1 (en) | 2008-03-14 | 2009-09-17 | Transgene S.A. | Antibody against the csf-1 r |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JP2518911B2 (en) | 1987-10-23 | 1996-07-31 | 森永乳業株式会社 | Compositions and methods for the treatment of cancer characterized by overexpression of the c-fms protooncogene |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0668914B1 (en) | 1992-06-09 | 2000-08-16 | Chiron Corporation | Crystallization of m-csf |
US20020193575A1 (en) * | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US6972323B1 (en) * | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
WO2000025803A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparations |
WO2001030381A2 (en) | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Use of csf-1 inhibitors |
AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
DE60233509D1 (en) | 2001-06-20 | 2009-10-08 | Fibron Ltd | FGFR3 BLOCKING ANTIBODIES, METHOD OF SCREENING THEREOF AND USES THEREOF |
US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
WO2004045532A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
AR045563A1 (en) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
WO2005070447A2 (en) | 2004-01-21 | 2005-08-04 | Chiron Corporation | M-csf muteins and uses thereof |
WO2005113596A2 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
EP2287310B1 (en) | 2004-07-22 | 2015-05-06 | Five Prime Therapeutics, Inc. | Compositions and methods using MGD-CSF in disease treatment |
WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
ATE454455T1 (en) | 2005-01-27 | 2010-01-15 | Five Prime Therapeutics Inc | GUIDING SEQUENCES FOR GUIDING POLYPEPTIDE SECRETION AND METHOD FOR PRODUCTION |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2007064437A2 (en) | 2005-11-10 | 2007-06-07 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
CN101379400A (en) | 2005-12-22 | 2009-03-04 | 诺华有限公司 | Soluble human M-CSF receptor and uses thereof |
CN101534858A (en) | 2006-01-05 | 2009-09-16 | 诺华有限公司 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
WO2008060610A2 (en) | 2006-11-17 | 2008-05-22 | Biogen Idec Ma Inc. | Systemic administration of colony stimulating factors to treat amyloid associated disorders |
WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
WO2008150383A1 (en) | 2007-05-30 | 2008-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | Csf-1r mutants |
US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
BRPI0818003A2 (en) | 2007-10-18 | 2019-09-24 | Novartis Ag | csf-1r inhibitors, compositions and methods of use |
EP2215482A2 (en) | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
US20110262425A1 (en) | 2007-12-12 | 2011-10-27 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
CA2780692C (en) | 2009-12-10 | 2018-09-11 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
CN102918061B (en) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | For antibody of people CSF-1R and uses thereof |
RU2617971C2 (en) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Antibodies to human csf-1r and use thereof |
AR080698A1 (en) | 2010-04-01 | 2012-05-02 | Imclone Llc | ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
AR084234A1 (en) | 2010-12-13 | 2013-05-02 | Novartis Ag | PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17) |
CA2852800A1 (en) | 2011-10-21 | 2013-04-25 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
JP6005751B2 (en) | 2011-10-21 | 2016-10-12 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | Regulation of macrophage activation |
WO2013169264A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
TWI713436B (en) | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
-
2011
- 2011-05-04 US US13/100,990 patent/US8206715B2/en active Active
- 2011-05-04 ES ES11778283T patent/ES2706412T3/en active Active
- 2011-05-04 MX MX2015007635A patent/MX355418B/en unknown
- 2011-05-04 SG SG10201604798SA patent/SG10201604798SA/en unknown
- 2011-05-04 CN CN202011184552.4A patent/CN112480256A/en active Pending
- 2011-05-04 TW TW105113540A patent/TWI595008B/en active
- 2011-05-04 TR TR2019/00368T patent/TR201900368T4/en unknown
- 2011-05-04 EP EP18151214.6A patent/EP3357510B1/en active Active
- 2011-05-04 EP EP11778283.9A patent/EP2566517B1/en active Active
- 2011-05-04 RS RS20190025A patent/RS58211B1/en unknown
- 2011-05-04 BR BR112012027994-7A patent/BR112012027994B1/en active IP Right Grant
- 2011-05-04 NZ NZ626610A patent/NZ626610A/en unknown
- 2011-05-04 EP EP20182161.8A patent/EP3943154A1/en active Pending
- 2011-05-04 CA CA2797399A patent/CA2797399C/en active Active
- 2011-05-04 KR KR1020127031635A patent/KR101838698B1/en active IP Right Grant
- 2011-05-04 DK DK11778283.9T patent/DK2566517T3/en active
- 2011-05-04 CN CN201610842693.8A patent/CN106977603B/en active Active
- 2011-05-04 TW TW100115607A patent/TWI542361B/en active
- 2011-05-04 CN CN201180022404.5A patent/CN103179985B/en active Active
- 2011-05-04 NZ NZ712765A patent/NZ712765A/en unknown
- 2011-05-04 NZ NZ603193A patent/NZ603193A/en unknown
- 2011-05-04 JP JP2013509230A patent/JP6008842B2/en active Active
- 2011-05-04 ES ES18151214T patent/ES2820517T3/en active Active
- 2011-05-04 PT PT11778283T patent/PT2566517T/en unknown
- 2011-05-04 KR KR1020187006772A patent/KR102105776B1/en active IP Right Grant
- 2011-05-04 KR KR1020207011504A patent/KR20200044999A/en not_active Application Discontinuation
- 2011-05-04 CN CN201610842863.2A patent/CN107011438B/en active Active
- 2011-05-04 SI SI201131627T patent/SI2566517T1/en unknown
- 2011-05-04 WO PCT/US2011/035231 patent/WO2011140249A2/en active Application Filing
- 2011-05-04 EA EA201291161A patent/EA036336B1/en not_active IP Right Cessation
- 2011-05-04 HU HUE11778283A patent/HUE042898T2/en unknown
- 2011-05-04 SG SG2012079133A patent/SG185035A1/en unknown
- 2011-05-04 TW TW107143066A patent/TWI713942B/en active
- 2011-05-04 LT LTEP11778283.9T patent/LT2566517T/en unknown
- 2011-05-04 AU AU2011248083A patent/AU2011248083B2/en active Active
- 2011-05-04 MX MX2012012790A patent/MX2012012790A/en active IP Right Grant
- 2011-05-04 TW TW106117413A patent/TWI651331B/en active
- 2011-05-04 TW TW109142917A patent/TW202112827A/en unknown
- 2011-05-04 SG SG10201911345WA patent/SG10201911345WA/en unknown
- 2011-05-04 PL PL11778283T patent/PL2566517T3/en unknown
-
2012
- 2012-05-04 US US13/464,503 patent/US8747845B2/en active Active
- 2012-10-23 IL IL222629A patent/IL222629B/en active IP Right Grant
-
2014
- 2014-04-30 US US14/266,209 patent/US9200075B2/en active Active
-
2015
- 2015-05-07 AU AU2015202477A patent/AU2015202477C1/en active Active
- 2015-10-27 US US14/924,568 patent/US9695243B2/en active Active
-
2016
- 2016-03-31 JP JP2016071180A patent/JP6196347B2/en active Active
- 2016-09-29 US US15/279,853 patent/US9957327B2/en active Active
- 2016-11-22 AU AU2016262662A patent/AU2016262662B2/en active Active
-
2017
- 2017-08-17 JP JP2017157498A patent/JP6529552B2/en active Active
- 2017-11-08 IL IL255524A patent/IL255524B/en active IP Right Grant
-
2018
- 2018-02-25 IL IL257712A patent/IL257712B/en active IP Right Grant
- 2018-03-26 US US15/935,621 patent/US10562970B2/en active Active
-
2019
- 2019-01-07 HR HRP20190047TT patent/HRP20190047T1/en unknown
- 2019-01-14 CY CY191100027T patent/CY1121102T1/en unknown
- 2019-02-01 AU AU2019200691A patent/AU2019200691B2/en active Active
- 2019-05-14 JP JP2019091364A patent/JP2019180413A/en active Pending
-
2020
- 2020-01-08 US US16/737,217 patent/US11186646B2/en active Active
-
2021
- 2021-09-14 JP JP2021149042A patent/JP2022008382A/en not_active Withdrawn
- 2021-10-28 US US17/513,109 patent/US20220153851A1/en not_active Abandoned
-
2023
- 2023-08-16 JP JP2023132563A patent/JP2023144055A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
WO2009112245A1 (en) | 2008-03-14 | 2009-09-17 | Transgene S.A. | Antibody against the csf-1 r |
Non-Patent Citations (11)
Title |
---|
ENDO ET AL., BIOTECHNOL. ADV., vol. 21, 2003, pages 695 - 713 |
HAMILTON, NAT. REV., vol. 8, 2008, pages 533 - 44 |
KITAURA ET AL., J. CLIN. INVEST., vol. 115, 2005, pages 3418 - 3427 |
LIN ET AL., SCIENCE, vol. 320, 2008, pages 807 - 11 |
OLMO ET AL., MOL. CANCER THER., vol. 5, 2006, pages 2634 - 43 |
PAULUS ET AL., CANCER RES., vol. 66, 2006, pages 4349 - 56 |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
SHERR ET AL., BLOOD, vol. 73, no. 7, 1989, pages 1786 - 1793 |
SITARAMAN ET AL., METHODS MOL. BIOL., vol. 498, 2009, pages 229 - 44 |
SPIRIN, TRENDS BIOTECHNOL., vol. 22, 2004, pages 538 - 45 |
TSUBOI ET AL., LEUKEMIA, vol. 14, 2000, pages 1460 - 1466 |
Cited By (338)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9879085B2 (en) | 2009-12-10 | 2018-01-30 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9499626B2 (en) | 2009-12-10 | 2016-11-22 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9499625B2 (en) | 2009-12-10 | 2016-11-22 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US10287358B2 (en) | 2009-12-10 | 2019-05-14 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US8999327B2 (en) | 2009-12-10 | 2015-04-07 | Hoffman-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9663580B2 (en) | 2009-12-10 | 2017-05-30 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9499624B2 (en) | 2009-12-10 | 2016-11-22 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US10077314B1 (en) | 2009-12-10 | 2018-09-18 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US10072087B2 (en) | 2009-12-10 | 2018-09-11 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
US9624302B2 (en) | 2010-03-05 | 2017-04-18 | Hoffmann-La Roche Inc. | Nucleic acids encoding antibodies against human CSF-1R |
US10030073B2 (en) | 2010-03-05 | 2018-07-24 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9617342B2 (en) | 2010-03-05 | 2017-04-11 | Hoffman-La Roche Inc. | Nucleic acids encoding antibodies against human CSF-1R and uses thereof |
US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
US9988458B2 (en) | 2010-03-05 | 2018-06-05 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US8747845B2 (en) | 2010-05-04 | 2014-06-10 | Five Prime Therapeutics, Inc. | Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
US9243066B2 (en) | 2011-07-18 | 2016-01-26 | University Of Melbourne | Use of M-CSF antibodies in the treatment of osteoarthritis or pain |
US10005840B2 (en) | 2011-07-18 | 2018-06-26 | Morphosys Ag | Method for treatment of osteoarthritis with C-Fms antagonists |
US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US10336830B2 (en) | 2011-12-15 | 2019-07-02 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
EP2812355A4 (en) * | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | Compositions and methods for using csf1r inhibitors |
JP2015510510A (en) * | 2012-02-06 | 2015-04-09 | ジェネンテック, インコーポレイテッド | Compositions and methods for using CSF1R inhibitors |
CN104093740B (en) * | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | Use the composition and method of CSF1R inhibitor |
CN104093740A (en) * | 2012-02-06 | 2014-10-08 | 弗·哈夫曼-拉罗切有限公司 | Compositions and methods for using CSF1R inhibitors |
JP2015514811A (en) * | 2012-04-26 | 2015-05-21 | バクシネックス インコーポレーティッド | Fusion protein to facilitate the selection of cells infected with specific immunoglobulin transgenic vaccinia virus |
US10662422B2 (en) | 2012-04-26 | 2020-05-26 | Vaccinex, Inc. | Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit |
AU2019204985B2 (en) * | 2012-05-11 | 2021-07-15 | Five Prime Therapeutics, Inc. | Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
US10982001B2 (en) | 2012-05-11 | 2021-04-20 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
JP2015517490A (en) * | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | Method of treating a condition using an antibody that binds colony stimulating factor 1 receptor (CSF1R) |
RU2670743C2 (en) * | 2012-05-11 | 2018-10-25 | Файв Прайм Терапьютикс, Инк. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
EP3539984A1 (en) | 2012-05-11 | 2019-09-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2013169264A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
RU2670743C9 (en) * | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
EP3679949A1 (en) | 2012-08-31 | 2020-07-15 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
JP2018197250A (en) * | 2012-08-31 | 2018-12-13 | ファイブ プライム セラピューティックス インコーポレイテッド | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
TWI713436B (en) * | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US10822421B2 (en) | 2012-08-31 | 2020-11-03 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
CN107759690A (en) * | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | With the method for the Antybody therapy symptom for combining the acceptor of colony stimulating factor 1 (CSF1R) |
US10221243B2 (en) | 2012-08-31 | 2019-03-05 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
JP2015533787A (en) * | 2012-08-31 | 2015-11-26 | ファイブ プライム セラピューティックス インコーポレイテッド | Method of treating a condition with an antibody that binds colony stimulating factor 1 receptor (CSF1R) |
RU2718751C2 (en) * | 2012-08-31 | 2020-04-14 | Файв Прайм Терапьютикс, Инк. | Methods of treating pathological conditions with antibodies which bind to the colony-stimulating factor 1 receptor (csf1r) |
EP2890398A4 (en) * | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
JPWO2014054820A1 (en) * | 2012-10-03 | 2016-08-25 | 株式会社カイオム・バイオサイエンス | Anti-human Dlk-1 antibody having antitumor activity in vivo |
US9856316B2 (en) | 2013-04-12 | 2018-01-02 | Morphosys Ag | Antibodies targeting M-CSF |
US10081675B2 (en) | 2013-04-12 | 2018-09-25 | Morphosys Ag | Antibodies targeting M-CSF |
US9192667B2 (en) | 2013-04-22 | 2015-11-24 | Hoffmann-La Roche Inc. | Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist |
EP4282881A2 (en) | 2013-08-30 | 2023-11-29 | UCB Biopharma SRL | Antibodies against csf-1r |
EA036255B1 (en) * | 2013-08-30 | 2020-10-20 | Юсб Биофарма Спрл | Anti-csf-1r antibodies and methods of use thereof |
JP2016529266A (en) * | 2013-08-30 | 2016-09-23 | ユーシービー バイオファルマ エスピーアールエル | antibody |
US10421814B2 (en) | 2013-08-30 | 2019-09-24 | Ucb Biopharma Sprl | Antibodies |
KR102303130B1 (en) * | 2013-08-30 | 2021-09-16 | 유씨비 바이오파마 에스알엘 | Antibodies |
EP4282881A3 (en) * | 2013-08-30 | 2024-02-21 | UCB Biopharma SRL | Antibodies against csf-1r |
AU2014314304B2 (en) * | 2013-08-30 | 2019-12-05 | Ucb Biopharma Sprl | Antibodies |
KR20160044018A (en) * | 2013-08-30 | 2016-04-22 | 유씨비 바이오파마 에스피알엘 | Antibodies |
JP2020005652A (en) * | 2013-08-30 | 2020-01-16 | ユーシービー バイオファルマ エスピーアールエル | Antibodies |
US9908939B2 (en) | 2013-08-30 | 2018-03-06 | Ucb Biopharma Sprl | Antibodies |
EP3549599A1 (en) | 2013-08-30 | 2019-10-09 | UCB Biopharma SPRL | Antibodies against csf-1r |
WO2015028455A1 (en) * | 2013-08-30 | 2015-03-05 | Ucb Biopharma Sprl | Antibodies |
US11512133B2 (en) | 2013-09-12 | 2022-11-29 | Hoffmann-La Roche Inc. | Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 |
WO2015100282A1 (en) | 2013-12-24 | 2015-07-02 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
EP3466949A1 (en) | 2013-12-24 | 2019-04-10 | Bristol-Myers Squibb Company | Tricyclic compound as anticancer agents |
EP3998079A1 (en) | 2014-06-06 | 2022-05-18 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US10987322B2 (en) | 2014-06-06 | 2021-04-27 | Flexus Biosciences, Inc. | Immunoregulatory agents |
EP3610924A1 (en) | 2014-06-06 | 2020-02-19 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US10975153B2 (en) | 2014-06-23 | 2021-04-13 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
WO2015200089A1 (en) | 2014-06-23 | 2015-12-30 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
EA037561B1 (en) * | 2014-06-23 | 2021-04-14 | Файв Прайм Терапьютикс, Инк. | Methods of treating diseases with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US11566076B2 (en) | 2014-10-29 | 2023-01-31 | Five Prime Therapeutics, Inc. | Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers |
KR20170074962A (en) * | 2014-10-29 | 2017-06-30 | 파이브 프라임 테라퓨틱스, 인크. | Combination therapy for cancer |
KR102636539B1 (en) * | 2014-10-29 | 2024-02-13 | 파이브 프라임 테라퓨틱스, 인크. | Combination therapy for cancer |
EP3835323A1 (en) | 2014-10-29 | 2021-06-16 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
US10618967B2 (en) | 2014-10-29 | 2020-04-14 | Five Prime Therapeutics, Inc. | Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer |
WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
US11932601B2 (en) | 2014-11-05 | 2024-03-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10106546B2 (en) | 2014-11-05 | 2018-10-23 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10206893B2 (en) | 2014-11-05 | 2019-02-19 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9598422B2 (en) | 2014-11-05 | 2017-03-21 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10533014B2 (en) | 2014-11-05 | 2020-01-14 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9643972B2 (en) | 2014-11-05 | 2017-05-09 | Flexus Biosciences, Inc. | Immunoregulatory agents |
EP3854394A1 (en) | 2014-11-05 | 2021-07-28 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
EP3725808A1 (en) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
US10040858B2 (en) | 2014-12-22 | 2018-08-07 | Five Prime Therapeutics, Inc. | Anti-CSF1R antibodies for treating PVNS |
WO2016106180A1 (en) | 2014-12-22 | 2016-06-30 | Five Prime Therapeutics, Inc. | Anti-csf1r antibodies for treating pvns |
US10730949B2 (en) | 2014-12-22 | 2020-08-04 | Five Prime Therapeutics, Inc. | Method of treating PVNS with anti-CSF1R antibodies |
WO2016106266A1 (en) | 2014-12-22 | 2016-06-30 | Bristol-Myers Squibb Company | TGFβ RECEPTOR ANTAGONISTS |
EP4249066A2 (en) | 2014-12-23 | 2023-09-27 | Bristol-Myers Squibb Company | Antibodies to tigit |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
KR102684038B1 (en) * | 2015-02-09 | 2024-07-10 | 유씨비 바이오파마 에스알엘 | pharmaceutical preparations |
WO2016140884A1 (en) | 2015-03-02 | 2016-09-09 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
US10167254B2 (en) | 2015-04-03 | 2019-01-01 | Bristol-Myers Squibb Company | IDO inhibitors |
WO2016161279A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
US10399932B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
US10399933B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
WO2016161269A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
US9790169B2 (en) | 2015-04-03 | 2017-10-17 | Bristol-Myers Squibb Company | IDO inhibitors |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
EP3283527B1 (en) * | 2015-04-13 | 2021-01-13 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
US11559583B2 (en) | 2015-04-13 | 2023-01-24 | Five Prime Therapeutics, Inc. | Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer |
TWI725966B (en) * | 2015-04-13 | 2021-05-01 | 戊瑞治療有限公司 | Combination therapy for cancer |
WO2016168149A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
EP3964527A2 (en) | 2015-04-13 | 2022-03-09 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016183115A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
WO2016183118A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
WO2017019757A1 (en) | 2015-07-28 | 2017-02-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
EP3733698A1 (en) | 2015-09-23 | 2020-11-04 | Bristol-Myers Squibb Company | Glypican-3 binding fibronectin based scafflold molecules |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017106291A1 (en) | 2015-12-15 | 2017-06-22 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
US10533052B2 (en) | 2016-07-14 | 2020-01-14 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US10077306B2 (en) | 2016-07-14 | 2018-09-18 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
US11591392B2 (en) | 2016-07-14 | 2023-02-28 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
US10640765B2 (en) | 2016-08-02 | 2020-05-05 | Vaccinex, Inc. | Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
US11542335B2 (en) | 2016-08-25 | 2023-01-03 | Hoffmann-La Roche Inc. | Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
US11337970B2 (en) | 2016-08-26 | 2022-05-24 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US11498968B2 (en) | 2016-12-22 | 2022-11-15 | Hoffmann-La Roche Inc. | Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment |
WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
EP4310082A2 (en) | 2017-01-20 | 2024-01-24 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
WO2018136700A1 (en) | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
JP2017125040A (en) * | 2017-02-28 | 2017-07-20 | ファイブ プライム セラピューティックス インコーポレイテッド | Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
WO2018183608A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
WO2018187613A2 (en) | 2017-04-07 | 2018-10-11 | Bristol-Myers Squibb Company | Anti-icos agonist antibodies and uses thereof |
WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
US10689388B1 (en) | 2017-04-21 | 2020-06-23 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
US10570138B2 (en) | 2017-04-21 | 2020-02-25 | Kyn Therapeutics | Indole AHR inhibitors and uses thereof |
US11358969B2 (en) | 2017-04-21 | 2022-06-14 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11607453B2 (en) | 2017-05-12 | 2023-03-21 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018213377A1 (en) | 2017-05-17 | 2018-11-22 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
US11236049B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of IDO inhibitors |
WO2019006283A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of ido inhibitors |
WO2019023459A1 (en) | 2017-07-28 | 2019-01-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
US12049520B2 (en) | 2017-08-04 | 2024-07-30 | Bicycletx Limited | Bicyclic peptide ligands specific for CD137 |
US10696650B2 (en) | 2017-08-17 | 2020-06-30 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
US11555026B2 (en) | 2017-08-17 | 2023-01-17 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046500A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
US11421034B2 (en) | 2017-09-13 | 2022-08-23 | Five Prime Therapeutics, Inc. | Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer |
WO2019055537A1 (en) | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
US11623932B2 (en) | 2017-09-22 | 2023-04-11 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
US11976125B2 (en) | 2017-10-13 | 2024-05-07 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
WO2019079261A1 (en) | 2017-10-16 | 2019-04-25 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
US10874743B2 (en) | 2017-12-26 | 2020-12-29 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11318205B1 (en) | 2017-12-26 | 2022-05-03 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11723980B2 (en) | 2017-12-26 | 2023-08-15 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2019133747A1 (en) | 2017-12-27 | 2019-07-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
US11952427B2 (en) | 2017-12-27 | 2024-04-09 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
US11932635B2 (en) | 2018-01-12 | 2024-03-19 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
US12006329B2 (en) | 2018-01-12 | 2024-06-11 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
WO2019147982A1 (en) | 2018-01-26 | 2019-08-01 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
US10988477B2 (en) | 2018-01-29 | 2021-04-27 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
US10793563B2 (en) | 2018-01-29 | 2020-10-06 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
WO2019160884A1 (en) | 2018-02-13 | 2019-08-22 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
US11655300B2 (en) | 2018-02-28 | 2023-05-23 | Ultrahuman Twelve Limited | Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof |
WO2019166596A1 (en) | 2018-02-28 | 2019-09-06 | Ultrahuman Twelve Limited | Csf1r binding agents |
JP2021514654A (en) * | 2018-02-28 | 2021-06-17 | ウルトラヒューマン トゥエルブ リミテッド | CSF1R binder |
CN111788229A (en) * | 2018-02-28 | 2020-10-16 | 超人十二有限公司 | CSF1R binding agents |
WO2019173587A1 (en) | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2019191295A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
WO2019200256A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
WO2019204257A1 (en) | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
WO2019243833A1 (en) | 2018-06-22 | 2019-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
US11453702B2 (en) | 2018-06-22 | 2022-09-27 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
US11912792B2 (en) | 2018-06-22 | 2024-02-27 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
WO2019243832A1 (en) | 2018-06-22 | 2019-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
WO2020006016A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
WO2020006018A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
US11897882B2 (en) | 2018-07-06 | 2024-02-13 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
US11401328B2 (en) | 2018-07-09 | 2022-08-02 | Five Prime Therapeutics, Inc. | Antibodies binding to ILT4 |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
WO2020069372A1 (en) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11117889B1 (en) | 2018-11-30 | 2021-09-14 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11807636B2 (en) | 2018-11-30 | 2023-11-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
WO2020127853A1 (en) | 2018-12-20 | 2020-06-25 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
JP2019089840A (en) * | 2019-02-22 | 2019-06-13 | ファイブ プライム セラピューティックス インコーポレイテッド | Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
US11746120B2 (en) | 2019-04-05 | 2023-09-05 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021025177A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021026179A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
WO2021041588A1 (en) | 2019-08-28 | 2021-03-04 | Bristol-Myers Squibb Company | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
US11028085B2 (en) | 2019-09-13 | 2021-06-08 | Nimbus Saturn, Inc. | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists |
US11034694B2 (en) | 2019-09-13 | 2021-06-15 | Nimbus Saturn, Inc. | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists |
US11078201B2 (en) | 2019-09-13 | 2021-08-03 | Nimbus Saturn, Inc. | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists |
US11021481B2 (en) | 2019-09-13 | 2021-06-01 | Nimbus Saturn, Inc. | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists |
US11548890B1 (en) | 2019-09-13 | 2023-01-10 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
WO2021058718A1 (en) | 2019-09-26 | 2021-04-01 | Roche Diagnostics Gmbh | Anti-csf-1r antibody |
WO2021101919A1 (en) | 2019-11-19 | 2021-05-27 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
US11591339B2 (en) | 2019-11-26 | 2023-02-28 | Ikena Oncology, Inc. | Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors |
WO2021108288A1 (en) | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
US11779578B2 (en) | 2019-12-17 | 2023-10-10 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11707457B2 (en) | 2019-12-17 | 2023-07-25 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
WO2021133748A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinolinonyl piperazine compounds useful as t cell activators |
WO2021133749A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as t cell activators |
WO2021133751A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
WO2021133750A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted bicyclic piperidine derivatives useful as t cell activators |
WO2021133752A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted heteroaryl compounds useful as t cell activators |
WO2021129673A1 (en) * | 2019-12-24 | 2021-07-01 | Adagene (Suzhou) Limited | Anti-csf1r molecules and use thereof |
CN114835811B (en) * | 2019-12-24 | 2024-03-26 | 宝船生物医药科技(上海)有限公司 | anti-CSF 1R molecules and uses thereof |
CN114835811A (en) * | 2019-12-24 | 2022-08-02 | 宝船生物医药科技(上海)有限公司 | anti-CSF 1R molecules and uses thereof |
TWI844756B (en) | 2019-12-24 | 2024-06-11 | 大陸商寶船生物醫藥科技(上海)有限公司 | Anti-csf1r molecules and use thereof |
WO2021139682A1 (en) | 2020-01-07 | 2021-07-15 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
WO2021178488A1 (en) | 2020-03-03 | 2021-09-10 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
US11932624B2 (en) | 2020-03-19 | 2024-03-19 | Kymera Therapeutics, Inc. | MDM2 degraders and uses thereof |
WO2021188769A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
WO2021194914A1 (en) | 2020-03-23 | 2021-09-30 | Bristol-Myers Squibb Company | Substituted oxoisoindoline compounds for the treatment of cancer |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2021247591A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
US11685750B2 (en) | 2020-06-03 | 2023-06-27 | Kymera Therapeutics, Inc. | Crystalline forms of IRAK degraders |
WO2021257643A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
US11857535B2 (en) | 2020-07-30 | 2024-01-02 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
WO2022038158A1 (en) | 2020-08-17 | 2022-02-24 | Bicycletx Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022120354A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022136266A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022136255A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022136257A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022148979A1 (en) | 2021-01-11 | 2022-07-14 | Bicycletx Limited | Methods for treating cancer |
WO2022167457A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
WO2022167445A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
US11773103B2 (en) | 2021-02-15 | 2023-10-03 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022216573A1 (en) | 2021-04-05 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
WO2022216644A1 (en) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023028235A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2023061930A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023150186A1 (en) | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
WO2024086718A1 (en) | 2022-10-20 | 2024-04-25 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11186646B2 (en) | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11778283 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9074/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2797399 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/012790 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013509230 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011778283 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011248083 Country of ref document: AU Date of ref document: 20110504 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127031635 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201291161 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012027994 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012027994 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121031 |